gsk corporate responsibility reportintroduction introduction contribution society report ceo chairman letter manage corporate responsibility important gsk governance principle stakeholder engagement stakeholder feedback respond government external affair membership trade association lobby expenditure political donation position key issue patient advocacy access medicine research ethical conduct employment practice human right environment community investment datum summary gsk corporate responsibility report introduction welcome gsk corporate responsibility report report explain approach wide range social ethical environmental issue associate business report performance webbase report available wwwgskcom gsk researchbase pharmaceutical company operation country prescription medicine vaccine overthecounter medicine consumer healthcare product business account world pharmaceutical market strong position therapeutic area include antiinfective asthma cancer cardiovascular depression diabete hivaids urology overview business annual report contribution society report explain approach significant corporate responsibility issue business include year medicine vaccine transform million life help increase access medicine medicine life expectancy lower death rate condition accessible poor patient develop develop heart disease stroke cancer medicine enable country people chronic disease enjoy good health research development maintain high lead life develop country healthcare ethical standard research publication advance mean people long risk research result disease polio major threat century ago sale marketing maintain high ethical standard sale marketing product continue research development new medicine vital illness cover employment practice approach treatment treatment human right environmental performance improve community investment discover develop new medicine expensive average cost million take report average year society rely report cover corporate responsibility activity pharmaceutical industry fund research performance update corporate majority medicine world responsibility report publish march datum relate develop pharmaceutical industry calendar year state gsk invest billion employ environmental datum collect people prescription medicine pharmaceutical consumer manufacturing site vaccine clinical development biological manufacturing site believe business make valuable pharmaceutical consumer site contribution society develop marketing distribution centre major office location medicine improve people live small office sale location include datum recognise research development manufacture site operation year sale medicine raise ethical issue note attach chart explain scope datum stakeholder listen concern address collection process parameter detail specify unit sale figure absolute number total consumption energy water etc datum environment health safety section report externally verify gsk corporate responsibility report introduction continue scope datum relate worldwide operation indicate use external guideline framework inform report relevant base report global reporting initiative guideline include gri index website element guideline cover aid comparison company report number change year report response feedback receive add summary reader overview approach key issue business year organize report accord principle year report progress principle reorganize section report easy navigate information marketing practice previously contain product customer incorporate ethical conduct section information previously contain leadership advocacy section embed report particular government external affair public private partnership major public health initiative information stakeholder engagement process stakeholder engagement gsk corporate responsibility report ceo chairman letter corporate responsibility fundamental delivering business goal interest shareholder remain paramount need respond stakeholder expectation help address societys healthcare challenge accept challenge solve problem healthcare provision develop world job company important contribution access medicine programme hivaid work world health organization eradicate lymphatic filariasis evidence effort make ship million preferentially price combivir epivir tablet develop country treatment hivaid donate million albendazole tablet prevention public private partnership develop pipeline new tuberculosis treatment year test new vaccine treatment malaria disease take devastating toll people africa corporate responsibility encompass address manage issue arise business activity good performance corporate responsibility support business strategy protect enhance relationship reputation doctor government patient gsk core business research production medicine make valuable contribution society people medicine literally lifesave satisfaction mean ignore issue associate research manufacture sale medicine publication research result marketing practice pharmaceutical sale representative use animal research environmental impact manufacturing process confident right policy programme place operate high standard report provide update progress corporate responsibility principle particular highlight include new policy authorship research article consumer advertising patient advocacy clinical trial register contain result gsk sponsor clinical trial seek view wide range stakeholder respond suggestion possible report contain new information number area response feedback receive stakeholder engagement hope report provide information seek corporate responsibility gsk welcome feedback sir christopher gent garni chairman chief executive officer gsk corporate responsibility report manage corporate responsibility corporate responsibility support business strategy prepare meet future expectation protect reputation help reduce business risk important management issue integrate daytoday operation approach inform frequent discussion range stakeholder include employee shareholder patient doctor government ngos information engagement process feedback receive stakeholder engagement government external affair corporate responsibility governance important gsk gsk corporate responsibility committee consist non achieve business goal gsk focus number executive director provide boardlevel forum business driver review external issue potential impact gsk business reputation provide highlevel build good product pipeline industry guidance approach issue member benefit patient consumer society corporate executive team include ceo continuously improve performance commercial attend crc meeting operational excellence committee meet time year review improve access medicine range policy progress principle policy extensive programme develop activity relate principle access develop world medicine standard ethical conduct research innovation global community partnership good place good people well review annually principle discuss regularly work year committee finding corporate responsibility encompasse achieve report board goal implement business driver mean committee meet time review operating way reflect value support activity number area include business success reduce business risk protect reputation access medicine way conduct business affect relationship animal testing patient consumer use product clinical trial develop country doctor prescribe medicine community partnership government regulate industry reputation people trust place product corporate responsibility report include final sign critical business report demonstrate stakeholder meet high reputation management ethical standard aspect work management significant business risk coordinate committed help address healthcare challenge risk oversight compliance council rocc maintain support retain licence rocc consider reputational corporate operate reputation standard operate responsibility risk employment practice impact ability background information crc rocc attract retain motivate good people risk management compliance gskcom business strategy annual report gsk corporate responsibility report manage corporate responsibility continue management structure believe daytoday glaxosmithkline management issue performance effectively business operation expert issue work gsk ceo committee board coordination provide crossfunctional team representative key business area representative senior corporate manager direct access executive strategy appropriate executive team team report member role oversee development implementation communication policy gsk ensure comprehensive consistent approach take organisation small team coordinate policy development report communication access stakeholder community environment advocacy socially responsible investment medicine engagement investment analyst detail environment health product emloyment human research ethic safety management ehs customer practice right innovation integrity management gsk committee sir christopher gent sir ian prosser lucy shapiro chairman committee sir ian nonexecutive shapiro ludwig professor sir christopher chief director smithkline beecham plc cancer research department executive officer vodafone chairman chief developmental biology group plc nonexecutive executive bass plc director beckman center director lehman brothers intercontinental hotels molecular genetic medicine holdings inc director chairman world travel stanford university school international advisory board tourism council nonexecutive medicine hold phd hakluyt senior deputy chairman plc molecular biology albert adviser bain nonexecutive director sara lee einstein college medicine corporation member cbi president committee gsk corporate responsibility report manage corporate responsibility continue principle community investment corporate responsibility statement principle positive contribution community identify key corporate responsibility issue operate invest health provide guidance employee standard education programme partnership aim bring company commit sustainable improvement underserve people develop develop world corporate responsibility statement engagement stakeholder principle want understand concern mission business improve quality interest corporate responsibility issue engage human life enable people feel well range stakeholder communicate openly live long focus need patient address issue way aim achieve mission product activity meet need different group allow enhance contribution society pursue legitimate business goal sustain economic performance operate environmentally responsible manner standard ethical conduct expect employee meet high ethical standard employment practice aspect business conduct activity treat employee respect dignity honesty integrity adhere principle encourage diversity ensure fair treatment comply applicable law regulation phase employment provide safe healthy work environment support employee perform research innovation potential responsibility undertake research innovate performance reputation business explore apply new technology human right constructively engage stakeholder concern commit uphold universal arise declaration human right oecd guideline ensure product subject rigorous mne core labour standard set scientific evaluation testing safety effectiveness international labour organisation expect quality standard supplier contractor business partner work gsk behalf comply exceed regulation legal standard applicable research development access medicine product continue research develop medicine product customer treat disease develop world find sustainable way improve access medicine promote product line high ethical disadvantaged people seek partnership medical scientific standard comply support activity applicable law regulation leadership advocacy caring environment establish challenging standard operate environmentally responsible manner corporate responsibility appropriate complexity systematic management environmental specific need business build external impact measurement performance set guideline experience share good practice challenging performance target improve seek influence remain competitive efficiency activity minimise material order sustain business energy use waste generate aim find opportunity use renewable material recycle waste gsk corporate responsibility report manage corporate responsibility continue stakeholder engagement stakeholder feedback engage different group interest section summarise feedback corporate way operate important responsible responsibility performance report business practice stakeholder include employee opinion leader sri investor employee investor patient doctor government ngos opinion leader survey multilateral organisation local community supplier opinion leader survey seek view scientific community listen people performance report open view action build telephone interview survey provide indepth trust address concern qualitative feedback design produce discussion take place normal course statistic second year commission business example scientist meet regularly survey nineteen participant take academic researcher pharmaceutical survey survey conduct company access medicine external organisation community investment programme collaborate finding ngo multilateral agency government community overall participant rate gsk performance group information available stakeholder highly interaction follow section access medicine animal research employee supplier government significant number wanted understand external affair approach corporate responsibility integrate business strategy management establish panel external stakeholder addition identify priority issue gsk provide ongoing advice comment ehs performance panel facilitate environment access medicines council independent ngo ehs management marketing ethic advertising seek stakeholder feedback inform research development new drug approach manage report issue clinical trial ethic publication trial result include drug pricing engagement socially responsible investor sri meeting sri environmental impact analyst discuss issue include access access medicine receive positive feedback medicine animal right supply chain sale access medicine programme develop marketing ethic clinical trial sri analyst country include preferential pricing research attend annual corporate responsibility disease develop world stakeholder briefing meet senior gsk manager want gsk adopt tiere pricing system middle survey corporate responsibility opinion leader income country extend access programme europe participant include develop country academic organisation customer government marketing ethic advertising respondent agencie investor medium multilateral agency feel report weak marketing ethic ngo participant want open survey gsk employee assess employee marketing practice ethical dilemma awareness issue seek view address key issue gsk research praise clinical trial register section contain summary feedback information want research ethic receive channel detail relationship medical profession respond research area choose drug pricing participant particularly want know price set criticism profit pharmaceutical company gsk corporate responsibility report manage corporate responsibility continue environment participant welcome breadth increase transparency feel programme quantitative target want issue gsk consider important business environment strategy material efficiency convey approach support overall programmes gsk set ambitious business strategy target implement programme address majority thought gsk report improve pharmaceutical environment provide detail stakeholder engagement reporting influence approach bring external participant ask comment voice report open challenge report like comprehensive coverage increase number performance indicator feedback investor gsk receive follow rating investor rate agency organisation rating association british insurers gsk give rating disclosure board responsibility policy relate social ethical environmental issue high possible rating dow jones sustainability index gsk include djsi world index come sector score ftsegood index gsk include ftsegood index eiris gsk rate good eiris draft report access medicine company achieve rating global sustainable gsk include global sustainable company base company corporate knight research innov strategic value advisor gsk pharmaceutical company list morley fund management gsk rating improve great disclosure management key impact area develop world disease access medicine ethical issue human right ehs business ethic oekom research gsk rate good sector oekoms corporate responsibility rating receive rating improvement sarasin bank gsk rate good performer industry base analysis company report covalence gsk rank company sector covalence ethical rank world big company gsk corporate responsibility report manage corporate responsibility continue feedback employee gsk approach authorship research article online survey send randomly medical journal response concern select gsk employee assess awareness ghostwriting performance report total take mainly relationship patient advocacy group response rate finding publishing list patient group receive show financial support gsk hear term corporate responsibility approach preferential pricing middle income corporate social responsibility country operate tiere pricing aware gsk produce corporate system responsibility report hear information pilot project assess report mygsk global news site gskcom benefit extend preferential pricing respondent feel issue importance product gsk ethical business conduct access information manage human right medicine health safety standard supply chain environment information environment strategy aware gsk ethic programme effort improve material efficiency access medicine health safety receive feedback suggestion process employment practice stakeholder disagree unable sale marketing practice community accommodate damaging interest partnership environment company shareholder possible explain look way increase employee awareness reason example need use animal approach report internal research communication programme undertake possible provide quantitative datum conduct followup survey measure meaningful indicator area performance impact continue review performance indicator respond publish build possible review corporate responsibility report continue engage stakeholder light stakeholder feedback address understand view approach point include provide well explanation corporate responsibility relate business strategy discussion government external affair challenge dilemma encounter pharmaceutical industry highly regulated additional content provide year regulation significant impact business follow area important engage debate legislation seek influence policy decision approach public policy political lobbying affect gsk fact major multinational corporation publishing position key policy issue approach government membership trade association view stakeholder ngos political donation size global reach access government marketing ethic policy policy maker recognise need use implement include datum number access responsibly benefit patient business employee discipline dismiss unethical public policy work govern external affair conduct code conduct back factual research approach advertising consumer analysis gsk external affair team monitor change approach payment healthcare practitioner propose reform legislation meet regularly conduct gsk clinical trial government official explain view range public policy issue gsk corporate responsibility report manage corporate responsibility continue lobbying issue affect pharmaceutical organization international investment ofii industry conduct trade pharmaceutical research manufacturers america association hire professional lobbyist phrma support public policy work lobbying expenditure gsk believe legally culturally appropriate gsk spend federal lobbying activity political donation legitimate way support information report political process political donation policy congress accordance lobby disclosure act govern activity area information donation figure include salary cost benefit give report annual report employee register lobby government account cost hire outside lobbying consultant addition policy govern interaction cost associate support lobby contact important stakeholder patient planning activity research background advocacy group necessary addition figure include cost run gsk washington government affair section describe office support staff portion trade association fee membership trade organisation associate federal lobbying cost activity deal federal government lobby expenditure collect datum lobbying expenditure political donation separately expense country position key issue political donation approach patient advocacy patient gsk make political donation corporate fund group support donation authorize law gsk company give systematic culturally appropriate contributed rating sustainability wwf survey political organisation canada lead company report lobbying practice majority donation donation high rating award company receive covered gsk policy political donation systematic rating coverage lobbying indicate system exist actively manage disclose gsk donation political party lobby public policy activity company likely political organisation european union discuss policy position material issue annual report information depth approach lobby contribution united states fully integrate company value business principle candidate finance primarily core business decisionmake contribution company individual ngos background information approach public party rule concern contribution policy available external affair section complex information exact process gskcom link appropriate legislation important note corporate fund membership trade association support candidate federal office gsk member trade organisation include gsk corporate fund give candidate state association british pharmaceutical industry abpi level state contribution allow biotechnology industry organization bio state law contribution accept important way company engage political european federation pharmaceutical industry efpia debate donate approximately intellectual property owner association ipo candidate stateheld office japan pharmaceutical association gsk contribution basis political lif swedish association pharmaceutical party gsk support candidate seek environment industry appropriately reward highrisk highinvestment industry believe free market principle gsk corporate responsibility report manage corporate responsibility continue intellectual property right state information issue cover website change political donation publicly available new issue update statement prepare current position statement find corporate contribution national political party wwwgskcom current issue cover include candidate run federal office prohibit law accordance federal election campaign clinical trial develop country act gsk political action committee pac counterfeit medicine facilitate voluntary political contribution eligible employee pac control gsk develop world challenge access medicine participate employee legal right importation medicine set pac contribution candidate intellectual property trip agreement political party federal state level gsk pac run employee contribution product diversion voluntary pac contribution subject strict preparation flu pandemic limitation example gsk pac patient advocacy contribute excess candidate federal office election patient advocacy group provide member support information live pac contribution determine governing board condition represent patient view advocate pacparticipate gsk employee issue affect patient interest important company require law pac contribution stakeholder gsk engage report federal election commission fec aim patientfocuse company agency oversee federal election activity half twoyear federal election cycle gsk commit ensure company work gsk employee pac contribute total ethically patient group group candidate state federal office independence credibility compromise global set principle support focus contribution canada gsk donate cad approximately gsk principle work patient group canada political candidate independence patient association province legal political judgement activity shall assure contribution country contribution country cooperative matter transparency vital joint policy undertake patient position key issue association glaxosmithkline shall base mutual respect trust wide range issue affect industry important clear position contribute glaxosmithkline shall refrain undue debate influence promote specific medicine service criticism company transparent work patient association position key issue gsk consider glaxosmithkline comply local definition lobby issue lawsgovernance public prepare position statement assume company focus case publish position communicate principle externally patient statement key issue website group internal training programme impractical inefficient issue ensure gsk employee act appropriately view happy patient group discuss position issue legitimate party gsk corporate responsibility report manage corporate responsibility continue patient advocacy leader summit pal way engage patient group regional summit north america individual european country time paneuropean summit brussels meeting patient group opportunity learn gsk tell company well support work typically range workshop attendee include session mediatraining share good practice patient group representative able discuss debate key issue relate patient advocacy healthcare policy attendee represent wide range patient group include dedicated cancer diabete hivaid respiratory disease mental health epilepsy gsk european patient group advisory board form consider voice patient strengthen europe sound board allow gsk forum consult patient group future policy direction company forum group raise policy issue important board independent chair european cervical cancer association representative series european groups usa europe gsk play lead role pharmaceutical industry healthcare stakeholder ensure patient group maintain independence gsk advocacy work govern association british pharmaceutical industry abpi code practice revise new code state write agreement patient group company work list patient group receive financial support company gsk list available website access medicine introduction access medicine develop world research development preferential pricing voluntary licencing investment public health initiative develop world research ethical conduct employment practice human right environment community investment datum summary gsk corporate responsibility report access medicine million poor people develop develop country obtain medicine need broad problem access healthcare remain significant challenge part world primary responsibility address problem rest government stakeholder include pharmaceutical industry important contribution section describe gsk support effort develop world improve access cover healthcare crisis part develop contribution develop world research world million people access adequate preferential pricing partnership voluntary licence food clean water political community investment important public health lack evident government initiative resource fund clinic staff need deliver basic healthcare aid pricing arrangement discount card middle pandemic problem bad create income country generation orphan deprive community patient assistance program discount card help great asset fit healthy productive people uninsure patient tackle crisis complex challenge poverty believe response right thing fundamental cause huge barrier progress make good business sense company adapt significant political extra funding need business practice address challenge new national international source aid leader future competitive market development build healthcare infrastructure talented people help attract retain welcome additional resource promise good people overall need adequate return believe responsibility government business activity enable invest intergovernmental agency supplement work bring new medicine vaccine patient ngo deliver healthcare need innovation underpin sustainability country pharmaceutical industry play company significant role support effort find innovative way help poor people important contribution develop develop country access medicine research development disease address ethical reputational commercial disproportionately affect develop country imperative reason access medicine believe gsk currently company research strategic business driver gsk new vaccine treatment hivaid support underserved community worldwide malaria world health organization priority donation fund practical support disease research conduct community investment public private partnership preferential pricing specially reduce price antiretroviral arvs antimalarial vaccine ship combined total million preferentiallypriced combivirand epivirtablet treatment hivaid develop world grant voluntary licence gsk grant seven voluntary licence manufacture supply generic version lead arvs treat hivaids africa gsk corporate responsibility report access medicine continue community investment public health initiative gsk create dedicated group pharmaceutical partnership foster effective healthcare include organisation focus disease develop major programme tackle lymphatic filariasis malaria world ddw include dedicated drug discovery hivaid diarrhoeal disease centre tre canto site spain clinical development expert ddw project research development prioritise accord social public health research development new drug benefit commercial return similar vaccine essential element improve health group exist vaccine organisation base belgium develop world effective treatment widespread lifethreatening disease unlike disease disproportionately affect exist treatment disease malaria develop world hivaid different affect effective drug resistance develop develop country commercial market new treatment encourage disease disproportionately affect develop investment require gsk industry leader world lack resource mean viable research hivaid treatment commercial market new treatment public private partnership ppps help address problem total gsk clinical programme medicine vaccine disease particularly relevant gsk collaborate ppp include develop world seven project disease medicine malaria venture mmv global alliance disproportionately affect develop country drug development gatb aeras global vaccine foundation aeras malaria vaccine initiative mvi international aids vaccine initiative iavi public private partnership gsk want continue invest research tackle venture mmv malaria vaccine initiative mvi disease blight develop world importantly new treatment result dilemma pharmaceutical company research effort accessible develop profitable sustain business continue world affordable price develop new medicine business model initial drug discovery disease develop work case prospect world ddw take place dedicated ddw commercial return unfortunately lack discovery centre tre canto gsk provide resource endemic country limited profit facility meet cost run site new treatment disease scientist employ gsk tre canto disproportionately affect develop country half subsidise partner organisation public private partnership ppp model medicine malaria venture mmv business public sector work offer global alliance drug development gatb solution problem research programme oversee joint steering committee representative gsk ppp company gsk provide partner organisation technology manufacture distribution expertise academic institution involve provide compound clinical development gsk research disease area knowledge public sector provide clinical regulatory manufacturing partner government organisation expertise resource global gate foundation help fund development supply network partner organisation help fund cost delivery cost ensure medicine run clinical trial address issue access people need fund usually channel distribution reduce cost development organisation medicine malaria get new product patient fast gsk corporate responsibility report access medicine continue development pipeline end disease relevant develop world focus preclinical activity phase phase phase iii market hiv protease retrovir epivir combivir ziagen inhibitor trizivir agenerase epzicom brecanavir kivexa lexivatelzir vaccine hiv streptorixs rotarix rotavirus malaria pneumoniae havrix hepatitis hepatitis paediatric engerixb hepatitis dengue fever cervarix twinrix hep cervical infanrixtritanrix dtp family cancer diptheria tetanus pertussis meningitis boostrix diptheria tetanus combination pertussis acellular polio sabin polio priorix measle mump rubella typherix typhoid hepatyrix typhoid hepatitis varilrix varicella hiberix haemophilus influenzae type mencevax acw meningitis malaria ntert butyl tafenoquine lapdap halfan malarone isoquine cda gsk chlorproguanil dapsone artesunate sitamaquine zenteldeworme agent visceral pentostamvisceral leishmaniasis leishmaniasis banocidelymphatic filariasis gsk india detailed information product pipeline find annual report isoquine enter phase progress malaria phase iib clinical trial malaria vaccine working medicine malaria venture child development year mmv world health organisation show unprecedented result new datum academic partner develop cda affordable fix publish lead medical journal lancet dose artemisinin combination treatment malaria show vaccine remain efficacious africa base gsk exist antimalarial lapdap month year clinical investigation november announce clinical result indicate need vaccine ready use cda likely effective drug resistant result indicate potential help save million falciparummalaria find africa cda children live support activity october bill progress phase lll trial chris hentschel ceo melinda gates foundation announce grant mmv comment result suggest cda path malaria vaccine initiative mvi extend public major weapon fight drug private partnership mvi gsk biological resistant malaria moving phase iii trial mark key new grant directly support clinical trial step development promise antimalarial africa funds gsk match million receive mvi help defray clinical development cost gsk corporate responsibility report access medicine continue gsk university california san gsk biological inhouse aids vaccine francisco receive mmvs project year award development project company proprietary falcipain project investigate new class compound adjuvant technology successful aid vaccine use malaria conducting need combine approach research identify candidate compound development mix result antiretroviral research gsk receive project year award december announce positive result pyridone project time study evaluate safety tolerability antiviral company successive year activity investigational protease inhibitor brecanavir follow extensive development work hope brecanavir expect enter phase iii development identify suitable candidate pyridone project approve useful treat patient half commence phase trial infect strain hiv resistant human multiple protease inhibitor significant chemical pharmaceutical development october terminate clinical trial aplaviroc undertake candidate gsk ntert ccr antagonist concern liver toxicity butyl isoquine malaria plan start clinical reviewing safety datum followingup patient study human progress red tablet version hivaid medicine clinical development programme tafenoquine combivirand epivir develop avoid diversion new antimalarial develop partnership medicine kind grant positive government walter reed army institute research scientific opinion european medicine agency additionally number target emea committee medicinal product human use potential potency malaria working opinion grant article tres canto site collaborator regulation allow emea scientific opinion medicine intend use outside hivaids emea grant certificate november gsk institut pasteur pharmaceutical product facilitate registration announce new european collaboration develop arvs develop country aid vaccine fuse gene human immunodeficiency virus hiv exist measle liquid formulation hiv medicine currently vaccine gsk license measle vaccine vector way treat young child technology institut pasteur entity easy use develop world set jointly develop aids vaccine project unicef state access solid support million million grant formulation facilitate treatment old european union include development child currently assess development production process experimental vaccine arv tablet score line easily clinical study study evaluate safety break small dose help physicians profile vaccine candidate second examine carer administer right dose efficiently safely safety vaccine produce immune child organise host meeting response hiv volunteer preexist september representative emea immunity measle clinical study begin fda mdecin sans frontire unicef year year collaboration discuss development score tablet child partner show great interest project early launch public private understand challenge development partnership international aids vaccine initiative consolidate available information iavi develop aids vaccine nonhuman document discussion regulator primate adenovirus vector technology collaboration half firstever aid vaccine research iavi major vaccine company facilitate research gsk enter material transfer agreement vaccine type hiv circulate predominantly international partnership microbicide ipm africa agreement iavi contribute gsk select provide proprietary antihiv technical expertise funding gsk iavi compound test possible use microbicide researcher form joint research team prevent transmission hiv gsk corporate responsibility report access medicine continue support clinical trial sponsor external rotavirus organisation uks medical vaccine rotarix prevention rotavirus research council national institutes health induce gastroenteritis launch mexico january nih hivcollaborative research programme approve country latin resourcepoor setting twentyfour trial include america early country brazil panama africa currently underway mainly focus venezuela salvador decide vaccinate public health issue patient currently form newborn baby distribute million dose form hiv collaborative studies latin america baby develop world rotavirus infection lead cause severe diarrhoea tuberculosis vomit gastroenteritis child kill million people year leading cause kill child year child death people aid develop world minute develop country rotarixwa new drug discover test large phase iii clinical trial perform year vaccine involve child launch rotarixhas license additional gsk announce joint drug discovery country worldwide continue seek regulatory partnership global alliance drug approval vaccine develop country development gatb lead public private partnership work treatment gatb aim cervical cancer accelerate discovery development affordable clinical trial datum present interscience drug shorten treatment effective conference antimicrobial agent chemotherapy multidrugresistant strain compound icaac candidate cervical cancer vaccine cervarix screen ensure take hiv show encourage result cervical cancer treatment people live aid common cause cancer death woman susceptible infection gatb support fulltime develop world current publish datum suggest scientist work exclusively drug programme vaccine reduce woman lifetime tre canto gsk contribute matching number risk develop cervical cancer plan apply staff remain overhead cost registration vaccine europe partnership gsk screening number compound international region possible use new class drug potency leishmaniasis medicine discover affordable continue intensive development accessible possible need sitamaquine new oral treatment visceral gsk continue provide fund faculty health leishmaniasis disease affect half million people sciences stellenbosch university south africa year develop world usually fatal research project project aim identify marker untreated gsk provide funding project predict patient respond quickly new treatment visceral leishmaniasis urgently treatment likely recur need current medicine impractical ineffective drug resistance sitamaquine october gsk aeras global vaccine show good efficacy pilot phase trial foundation announce new publicprivate partnership phase iib study start investigate shorter develop gsk candidate vaccine show treatment course positive result enable phase iii promising result earlystage clinical trial gsk study aeras plan conduct additional trial europe involve adult previously infect vaccinate bacillus calmettegurin bcg study begin africa locations test safety efficacy hivaid malaria leishmaniasis dengue fever hepatitis vaccine candidate population highly affected meningitis cervical cancer pneumonia gsk corporate responsibility report access medicine continue preferential pricing gsk vaccine available preferential price work multinational organisation unicef poverty lack political insufficient medical world health organization pan american infrastructure hospital clinic health worker health organisation government nongovernmental big barrier access healthcare develop organisation provide appropriate affordable country vaccine develop world include basic affordability medicine important polio vaccine specially develop combination element ability government vaccine target disease patient pay medicine solve problem billion vaccine ship go require government intergovernmental agency develop world significant additional financial resource available progress second element price medicine ship million preferentiallyprice sell area gsk help address make combivirtablet majority go key medicine available develop country africa increase year affordable price major commitment previous year combine shipment preferential pricing include notforprofit epivirgrew tablet number price world poor country discount arrangement place supply price wealthy develop country factor preferentially price arvs change significantly supply chain taxis tariff distributor year markup significant impact price medicine factor control overall shipment relatively low consider scale address government hivaid epidemic growth encourage doctor hospital clinic need treat hivaids malaria treatment available patient ensure well uptake preferentially notforprofit price public sector customer price medicine notforprofit organisation develop country subsaharan africa country eligible global fund pepfar project mean notforprofit price offer country notforprofit price sustainable profit cover manufacture distribution cost continue supply longterm notforprofit price comparable generic combivir lead arv available day include delivery cost late june pricing report mdecin san frontiresshow average cost generic equivalent day lowest price generic equivalent cost day generic price include shipping cost insurance include price negotiate public sector price middleincome develop country casebycase basis httpwwwaccessmedmsforgprodpublicationsaspscntid contenttypepara gsk corporate responsibility report access medicine continue shipment preferentially price combivir epivir exclude divert stock shipment preferentially price combivir epivir exclude divert stock million tablet shipment combivir epivir total stelbat snoillim gsk corporate responsibility report access medicine continue difficult estimate number patient treat eligibility notforprofit price result preferential pricing agreement gsk control healthcare provision report notforprofit price target country unle accelerate access initiative aai suggest need great available resource september people live lacking develop hivaids develop country receive treatment country ldc subsaharan africa ssa antiretroviral supply seven total country addition private pharmaceutical company aai compare employer subsaharan africa provide care people treatment include treatment uninsured staff purchase patient africa remains arvs notforprofit price notforprofit price growth encouraging offer country coordinate middle income country mechanism ccm projectsfully fund global afford supply product low price fund project fund president world poor country adequate emergency plan aid relief pepfar return wealthy market focus country total notforprofit price recognise middleincome country need offer country assistance target country seek notforprofit negotiate preferential pricing arrangement arrangement facilitate access core public middleincome country casebycase basis employee teacher nurse police fire believe good approach disease burden fighter cover private health resource available address vary significantly insurance scheme country country arrangement combine viable negotiate price private health sector sustainable commercial return gsk increase casebycase basis depend revenue affordability healthcare system concern sale private market maintain local presence develop country muchneede infrastructure develop introduce discount card senior citizen country local capacity develop world unable provide essential service train healthcare worker use product product antidiversion measure support safety monitor registration launch product diversion notforprofit medicine new product illegally ship sale wealthy country undermine ability provide notforprofit price list product cover notforprofit price deny treatment intend patient poor eligible country available website country introduce different packaging tablet colour notforprofit medicine help prevent product diversion special trilingual access expect find price pack approve combivir epivirand trizivir number factor affect accessibility country receive regulatory medicine lack healthcare capacity infrastructure approval red epivirand combivirtablet fundamental barrier make country gsk arvs register product available affordable price expand eus antidiversion regulation company usage appear preference register product regulation product similarly price generic evaluate extend preferential pricing finding pilot use inform set pilot project collaboration ngo strategic review business subsaharan africa tanzania uganda nigeria zambia malawi assess impact extend preferential pricing wide range product antibiotic asthma treatment vast majority global fund project country coordinate mechanism ccm project gsk corporate responsibility report access medicine continue voluntary licensing investment public health initiative want play active role address healthcare gsk support public community health initiative crisis develop country believe preferential develop country donation preventative pricing arrangement good way medicine financial practical support able ensure delivery safe quality product focus charitable support effort tackle affordable price long need major disease lymphatic filariasis focus effort situation voluntary elephantiasis hivaid malaria licence help increase supply medicine phase education programme reduce diarrhoearelate voluntary licence enable local manufacturer disease partner nonprofit organisation produce sell generic version product progress effort november sign licencing agreement information community investment universal corporation kenya total programme community investment sign seven licencing agreement antiretroviral arvs africa hivaid devastating progress impact include vls kenya eliminate lymphatic filariasis south africa grant aspen gsk founding partner global alliance pharmacare october cover part eliminate wwwfilariasisorg disfigure disease africa subsaharan africa prevalent tropical country world lead cause permanent disability decision grant depend number factor include severity hivaid epidemic global alliance partnership country local healthcare provision economic pharmaceutical company world health manufacturing environment vls universal organization ministry health ngo community solution hivaid specific response particular organisation aim totally eliminate set circumstance commit provide dose discuss vls potential partner casebycase albendazole antiparasitic drug prevent basis select appropriate licensee key transmission need treat billion need sure manufacturer able people risk country open new provide longterm supply goodquality medicine albendazole manufacturing facility cape town south implement safeguard prevent diversion africa capability support medicine wealthy market elimination effort atrisk country voluntary licence holder combine active ingredient donate million albendazole treatment license license active worth million million value wholesale ingredient produce fix dose combination price countrie new country join use food drug administration fast track programme donate million approval process arvs accelerate availability treatment reach million people generic arvs pepfar president emergency plan give million million grant aid relief program programme africa support global alliance eliminate discussion use team gsk employee help global alliance compulsory licence intellectual property advocacy research community mobilisation education right take away right holder compulsory initiative license flexibility world trade december gsk programme eliminate organisation trip agreement intellectual property honour corporate social responsibility humanitarian purpose gsk inaugural annual scrip award recognise believe widespread use compulsory licence performance excellence global pharmaceutical undermine intellectual property framework biotech industry counterproductive long term new treatment especially commercial market exist hivaid depend protection intellectual property gsk corporate responsibility report access medicine continue positive action hivaid gsk african malaria partnership recognise need support community african malaria partnership support education affect hivaid longstanding commitment behaviour change program african country community investment set partnership freedom hunger amref positive action aim strengthen capacity plan international community base organisation provide hivaids gsk invest million african malaria healthcare service increase number people partnership year expect benefit come forward testing treatment reduce million people encourage effective stigma discrimination recognise involve people prevention prompt treatment particularly affect hivaid key control hiv pandemic child pregnant woman launch new positive action programme india give million kenya mexico year grant new partner malaria consortium positive action programme run country ngo launch mobilise malaria initiative aim positive action support reach india project focus attention malaria generate political aim hivaids prevention financial business commitment sustain fund combat education available million poor woman rural disease generate medium coverage increase india gsk give number ngo community organisation engage develop capacity community organisation tackle malaria african community selfhelp group reach woman rural area knowledge tool need prevent year expect benefit woman transmission malaria million family member reach india project personal hygiene sanitation education phase freedom hunger support catholic relief year million people die diarrhoea service positive action relate disease children develop country kenya gsk give million million death easily prevent well year integrate hivaids treatment support service hand washing sanitation general healthcare clinicsthis enable phase help reduce diarrhoearelate disease patient avoid stigma visit hiv clinic few encouraging school child wash hand gsk kenyans know hiv status fear establish phase invest million stigmatisation significant barrier people seek million programme phase run testing diagnosis treatment service positive action partnership amref plan international focus train healthcare professional ministry health education creation patient selfhelp group increase awareness support patient stick programme impressive result example treatment regime programme collaboration study amref kenya show year gsk amref african medical research child participate school wash foundation elizabeth glaser pediatric aids foundation hand toilet compare national empowerment network people live nonparticipating school hiv aids kenya phase extended bangladesh mexico launch threeyear project operate country bangladesh asian international hivaids alliance mexican partner country phase year colectivo sol project aim improve quality programme implement school reach life people hivaid reduce stigma child gsk work new partner discrimination help people protect bangladesh save children usa phase hivaids education awareness raise integrate save children exist school health nutrition programme ensure project long information arrangement supply hivaids term sustainability gsk funding finish medicine preferential price develop country preferential pricing gsk convene phase steering committee representative partner organisation help source kenya demographic health survey expand programme country httpwwwmeasuredhscomhivdata gsk corporate responsibility report access medicine continue develop world january gsk pharmaceutical company create new card improve access access medicine issue develop medicine uninsured americans senior world develop country patient accesscard provide saving afford medicine need particular medicine approximately million problem people people uninsured people health insurance gsk develop patient assistance eligible enrol participate company enrol program discount card help patient people receive insurance prescription worth million base wac introduce discount card middle gsk assist patient income country enable qualify patient obtain prescription worth million prescription medicine discount price orange card middle income country program gsk introduce orange cardsprovide discount patient assistance program provide prescription medicine certain gsk prescription medicine eligible patient lowincome uninsured patient free minimal cost bulgaria lithuania ukraine nature gsk operate programme include commitment discount vary country depend accesswhich cover cancer treatment bridge need patient way healthcare accesswhich cover medicine outpatient system operate patient register phone orange cardin ukraine give asthma patient advocate receive medicine local chronic obstructive pulmonary disease patient pharmacy mail order patient average discount receive gsk medicine worth million gsk seretide asthma medicine asthma patient programme compare million age suffer disability affect value medicine calculate chernobyl nuclear disaster eligible eligibility wholesale acquisition cost wac assess patient doctor patient receive gsk pharmaceutical company medicine participate pharmacy hotline offer card provide saving medicine lowincome number set help patient find near senior citizen disable people know orange pharmacy patient enrol receive cardthis enable people buy gsk outpatient discount worth prescription medicine discount lithuania orange cardgive senior citizen orange cardholder receive average discount patient copayment prescription save million base wac gsk prescription medicine far gsk pharmaceutical company patient apply orange cardand establish rxcard provide discount pharmacy register participate prescription medicine lowincome senior patient receive discount worth citizen eligible medicare december widen group eligible people receive gsk prescription orange cardto include disabled people programme save million base wac gsk orange cardwas introduce bulgaria access programme change significantly lowincome patient chronic disease launch new medicare prescription asthma chronic obstructive pulmonary disease drug coverage programme orange cardand diabetes card holder receive average rxprogramme finish december discount gsk prescription medicine patient eligible new medicare patient receive discount worth euro programme report rollout million million change year gsk corporate responsibility report access medicine continue summary gsk discount programme country gsk programme number patient value benefit patient patient assistance program free receive million minimal cost medicine lowincome prescription uninsure patient orange card discount lowincome receive million senior citizen disable people prescription discount lowincome receive million senior citizen joint industry programme prescription access discount receive million lowincome uninsured patient joint prescription industry programme bulgaria orange card discount lowincome patient million patient chronic disease receive prescription lithuania orange card discount senior citizen enrol disabled people ukraine orange card discount asthma enrol medicine patient case study prescription combat global disease medicine malaria venture mmv manage large portfolio malaria drug research malaria kill million people year history project different stage child develop country human development gsk partner mmv toll malaria cost africa billion year academic institution biotech firm lose growth account public pharmaceutical company health spend mmv project cda affordable fix recently little research devote dose combination treatment malaria africa cda malaria develop world disease base gsk lapdap new develop country money malaria treatment develop ppp pay new medicine little incentive clinical trial show cda effective company develop drug resistant malaria year public private partnership ppps similar partnership malaria vaccine initiative transform research landscape malaria accelerate development malaria vaccine develop world disease gsk involve gsk clinical trial show partnership ppp public sector vaccine mosquirix efficacious child aged organisation include government private month period time vaccine foundation bill melinda gates prove efficacious parasitic disease foundation help fund research help human result demonstrate feasibility develop country purchase new product develop efficacious vaccine malaria register significantly contribute reduce intolerable global burden disease research introduction access medicine research animal research conduct clinical trial training auditing clinical trial clinical trial information result ethical conduct employment practice human right environment community investment datum summary gsk corporate responsibility report research research development new medicine vaccine core business make significant contribution society new medicine vaccine bring huge benefit health quality life million people year continue remain important debilitate life threaten illness effective treatment treatment significantly improve invest billion billion animal research employ people goal animal research essential understand disease build good product pipeline industry evaluate safety effectiveness new medicine research aim meet unmet medical need pipeline vaccine give people include compound potential major contribution healthcare develop country regulation require new medicine test access medicine work essential animal test human safety reason little return investment new vaccine test animal time treatment area seek partner help fund new batch produce estimate animal research project account gsk research expenditure process seek view gsk animal research laboratory europe japan patient inform research focus patient need singapore research drive innovation bring commercial success total animal research conduct external contractor behalf percentage remain relatively recognise biomedical pharmaceutical constant year research raise ethical concern use new technology objective report clinical trial animal gsk rodent result commit attain high ethical rat mice guinea pig rabbit remain scientific standard work section include fish ferret pig dog cat primate explain approach goal use animal scientifically animal research effort reduce refine necessary use animal possible replace animal testing minimise distress animal research laboratory subject strict internal legal control gsk conduct clinical trial ensure gsk commit reduction refinement sponsor clinical trial carry replacement achieve high standard ethical standard irrespective animal welfare run award programme encourage conduct implementation share good practice train auditing clinical trial train industry communicate approach gsk employee involve clinical trial interested party check trial carry good clinical practice approach impact despite significant gcp standard increase activity number animal clinical trial information result publicly gsk laboratory broadly similar disclose trial information result journal year ago article gsk clinical trial register public database background information approach new technology available website gsk corporate responsibility report research continue animal gsk mouse rat guinea pig rabbit rodent animal gsk animal mouse rat guinea pig rabbit rodent gsk corporate responsibility report research continue change activity compare change number animal gsk research laboratory figure normalise level change activity compare change number animal gsk research laboratory year animal acivity total animal research conduct external contractor behalf percentage remain relatively constant year ecni egnahc activity animal gsk corporate responsibility report research continue share good practice commit reduce number animal gsk participate study associate study refining study minimise pain parliamentary group animal welfare use maximise information obtain animal animal vaccine test human information replace animal study alternative method work develop new test vaccine possible replacement primate mouse test oral polio vaccine include final report publish recent gsk advance research technique support march animal welfare httpwwwapgaworguserimagesvaccinetestingpdf redesign animal study refining testing annual gsk laboratory animal welfare prize method output biomarker similar recognise external researcher laboratorie develop measure blood test human clinical trial good new technique implement obtain animal alive increase prize reduce total number animal need award new national centre obtain datum industry partner association use radiotelemetry technology enable british pharmaceutical industry fund new continuous measurement blood threeyear post national centre pressure heart rate temperature encourage share industry good practice disturb restrain animal regulation internal control observation nighttime activity marmoset laboratory comply strict national law monkey result improvement nest guideline code conduct animal welfare box rest sleep regulator carry regular unannounced inspection website background information site check standard animal care implementation gsk ensure appropriate use animal propose animal training awareness test review ethical review committee provide extensive training staff gsk laboratorie external laboratory conduct involved care use animal research behalf follow code practice number initiative increase awareness animal animal research include good practice standard welfare example produce quarterly bulletin animal care use review update review recently publish journal news item code practice policy subject ukbased committee good practice define combination gsk scientist statistician senior manager animal currently know scientific literature technician veterinarian encourage culture publish recommendation knowledge gsk seminar production promotion expert outside gsk independent recommend practice guideline scientific accreditation association accreditation procedure animal welfare assessment laboratory animal care aaalac animal welfare award encourage employee find international way laboratory demonstrate alternative animal research award present meet good practice gsk chairman recognise employee laboratory accredit aaalac outstanding advance implement include animal laboratory belgium italy awards development spain present vast majority use advanced medical imaging system minimise animal gsk aaalac accredit facilities animal use aim achieve aaalac accreditation gsk animal technician award andrew laboratory conduct animal research blake tribute award seriously ill medical research communicating approach national patient group support humane animal testing clearly sensitive issue animal research paper improvement people hold strong view believe important housing husbandry welfare ferret gsk gsk corporate responsibility report research continue explain need animal research open clinical trial carry conduct accord good clinical practice gcp guideline develop international conference gsk take twoyear detailed ethical review harmonisation ich principle contain nuffield council bioethics ethic research world medical association declaration helsinki involve animal publish conclude ethical principle medical research involve human animal useful model study specific aspect subject ich guideline provide human biology disease likely effect internationally accept ethical scientific quality chemical medicine human standard designing conduct recording usefulness animal model judge report trial cover issue selection casebycase basis type research testing training trial investigator gain informed consent report recommend information trial participant monitor quality assurance available goal welfare implication animal policy ensure medical practitioner research alternative scientific method enable run gsksponsore clinical trial select interested party judge specific type recompense appropriately policy payment research justifiable emphasise importance healthcare practitioner institution conduct gsk alternative animal research development sponsor gsksupporte clinical study state new alternative method condemn use clinical trial investigator select solely violence intimidation oppose animal qualification conduct clinical research history research gsk endorse report finding gsk product take account laboratory host visit school college animal payment practitioner reflect fair market value welfare organisation work perform payment offer visit school visit influence judgement enrol school community group discuss issue maintain participant clinical study animal research engage regularly animal welfare standard clinical trial organisation investor interested party trial protocol plan clinical trial contribute debate medium conduct review external regulatory agency article animal research impact relevant country require protocol animal right extremism financial time note consider relevant ethical review committee glaxosmithkline lead pharmaceutical industry remit cover site study place cautious openness use ethic review committee compose lay people animal october medical professional scientist assess accept legitimate right lawfully protest trial justify design animal research free society condemn conduct accord appropriate ethical standard use violence intimidation oppose ethic committee power reject stop animal use clinical trial safety datum routinely collect conduct clinical trial development programme report regulator line applicable regulation safety effectiveness new medicine review gsk ongoing basis safety evaluate human clinical trial signal gsk global safety board responsible approve marketing regulator approval approval pivotal protocol internal assessment trial demonstrate product safe effective issue relate patient safety arise benefit outweigh risk potential development programme audit clinical trial ensure effect conduct appropriate standard new product typically test training auditing clinical trial stage clinical trial involve healthy individual patient relevant disease project clinical development gsk corporate responsibility report research continue clinical trial outside western europe number scale trial take place north north america america western europe increase difficult gsk conduct clinical trial answer scientific question find experienced investigator able start meet regulatory requirement seek conduct trial recruit suitable patient quickly few patient clinical trial enrol trial country easy find participant speed research process population relevant scientific question help ensure new medicine patient quickly result generalise broad patient country few population medicine north america western high quality datum obtain europe make good candidate clinical cost minimise trial easy assess effect medicine test clinical trial place western europe north america trial develop country conduct regulator world require significant evaluate new medicine different disease amount clinical datum approve medicine include disease previously consider impact pool available patient north prevalent develop world america western europe increase cost common develop country associate conduct clinical trial look increase number patient recruit country recruitment cost patient country trial central eastern europe asia south america outside north america western europe lower south africa addition gsk ongoing allow pharmaceutical company meet commitment invest research development regulatory requirement financial demand target disease disproportionately affect relevant population develop country malaria clinical trial gsk commit invest disease develop country usually require develop disproportionately affect develop country investigational compound important note access medicine compound usually clinical trial investigational medicine test clinical trial develop country conduct country know outset disease prevalent medicine relevant intent pursue registration local population example incidence malaria medicine available use country develop world low mean development medicine conduct scientifically robust clinical trial new gsk start perform trial region malaria treatment develop country central eastern europe south africa latin america concern trial region part asia reason carry high standard healthcare infrastructure clinical trial capability western europe north america gsksponsore region improve significantly recent clinical trial conduct ethical standard year example physician work irrespective location study meet international develop country train educate national regulatory legislative requirement global standard clinical trial conduct accordance principle good readily conduct effectively monitor clinical practice gcp principle contain country world medical association declaration helsinki ethical principle medical research involve human change living standard mean disease previously subject common develop world hypertension diabetes prevalent develop leastdevelope country additional country include patient ethnic measure need example culture background enable develop medicine truly western society comply global fashion help evaluate new ethical legal requirement additional step take treatment suitable different ethnic group match objective inform consent local culture example local leader andor family member need involved gsk corporate responsibility report research continue posttrial treatment detailed training record routinely ask happen patient request regulatory authority undertake treatment end trial inspection assess competence employee undertake clinical trial important realise gsk general responsible provision nationally license gsk internal audit department conduct audits gsk medicine treatment approve use system process involve conduct trial trial reason gsksponsore clinical trial audit clinical research organisation chronic condition carry investigator perform clinical research behalf assure outset national healthcare system audits conduct able provide responsible continued audits investigator site conduct gsk care trial participant trial importantly sponsor trial represent approximately patient initiate nationally license medicine investigator site participate pivotal clinical trial trial chronic disease need assure pivotal clinical trial trial provide suitable alternative primary datum regulatory approval base medicine available trial audits internal gsk system process patient derive measurable medical benefit manage clinical trialsdata gsk recognise circumstance audits clinical research organisation carry compelling medical rationale patient clinical trial gsk behalf derive measurable medical benefit investigational compound medicine audits gsk medical department base specific approve clinical trial continue country receive compound example illness audits conduct response suspect treat life threaten seriously debilitate irregularity treatment available significant risk switch patient alternative audits result finding need treatment case posttrial treatment investigation investigator report investigational compound provide regulatory agency appropriate oversight example clinical trial audit result report quarterly risk set gsk commit provide investigational management compliance board annually compound long necessary gsk audit committee concern issue identify compound approve license country audits fully investigate appropriate action take include retrain severe case dismissal individual concern training auditing clinical trial development new training programme procedure provide training ensure clinical trial prevent reoccurrence trial datum perform high ethical quality standard audit analyse conduct clinical trial ensure carry accord good clinical practice gcp guideline inspection investigator clinical research organisation independent ethic committee iecsinstitutional review employee involve design conducting board irb sponsor clinical trail carry monitor gsksponsore trial train gcp regulatory authority ensure safety trial training mandatory employee participant quality datum trial complete require training start conduct accord gcp change job training inspection gsk investigator activitie related gcp training activity represent gsk conduct clinical study successful completion elearning module instructorle course relate gcp employee complementary worker gsk corporate responsibility report research continue clinical trial information result gsk follow phrma principle conduct clinical trial communication clinical trial result clinical trial widely available result commit timely communication healthcare practitioner use evaluate result product approve marketing use medicine publicly disclose information ongoing trial possible publish trial result peer review scientific medical journal conference ongoing clinical trial abstract proceeding research publicly available internetbased registration ongoing healthcare community obtain late information clinical trial provide stimulus increase treatment participation clinical research provide important reference point interested party track gsk guarantee publication method subsequent disclosure clinical trial result discretion journal editor conference organiser reason launch gsk online gsk legally require post summary protocol clinical trial register supplement prescribing information ongoing study treatment information publication scientific literature lifethreatening disease conduct register contain result protocol information investigational new drug application national gsksponsore trial market medicine institute health website wwwclinicaltrialsgov provide reference publication appeared additional commitment post medical journal use internet access protocol summary patient clinical trial irrespective register country involve initiate november ongoing july clinicaltrialsgov concern ghost write journal end protocol summary article doctor name article write actively recruit clinical trial clinicaltrialsgov pharmaceutical company gsk approach authorship acknowledgement article posting meet requirement international consistent journal guideline committee medical journal editor nonphase iii determine base level contribution study trial policy delay registration certain datum design datum acquisition analysis interpretation element exceptional basis write revise manuscript name competitively sensitive senior author paper actively participate clinical trial result draft process lead content development pharmaceutical company legally require disclose manuscript senior author work closely relevant data clinical trial appropriate coauthor retain final approval authority regulatory authority seek approval new manuscript gsk staff contractor contribute product development manuscript external author name article approval sponsor continue obligation provide regulatory authority update safety activity information clinical trial ensure regulator end clinical trial accurately assess safety effectiveness new summary gsk clinical trial register medicine monitor safety safety efficacy httpctrgskcoukwelcomeasp include information provide doctor prescribe clinical trial major market product information approve regulator complete merger gsk complete merger likely inform addition need use way medical judgement continue populate appropriately communicate result clinical trial register clinical trial relate market healthcare practitioner use evaluate medicine complete use medicine gsk corporate responsibility report research continue number publication gsk clinical trial gsk clinical trial register cumulative total number publication gsk clinical trial gsk clinical trial register cumulative total year publication snoitacilbup rebmun objective publish trial result new product gsk comply corporate policy procedure month product reach market establish fulfill commitment publish result trial complete product information clinical research activity available approve marketing year trial completion public addition actively involve sharing view experience clinical trial registration independent assessment documentation process advisory board process establish procedure gsk populate clinical world health organization establish trial register httpctrgskcoukwelcomeasp international clinical trial registry platform conduct external organisation continue httpwwwwhointictrpen engage service organisation ensure gsk corporate responsibility report research continue case study diabete research gsk potent compound test human clinical trial avandia treatment type diabete gsk sell medicine avandiawa launch complex disease type diabetes outcome research begin failure rate research high despite significant year early investment pharmaceutical industry new drug introduce year type diabete cause inability insulin sensitiser avandia produce insulin insulin resistance available avandiaha inability respond insulin available cause seven million people worldwide help rise blood sugar devastating control disease improve quality life consequence patient include blindness heart attack stroke diabete research gsk stop invest million large beecham gsk legacy company begin research outcome study assess effect avandiaon type diabete time longterm complication diabete type oral sugarlowering drug available prevent atrisk people work stimulate body produce develop disease new combination insulin help liver control blood treatment avandametand avandaryl sugar level treatment successful launch combine avandia diabetes everybody furthermore diabete treatment treatment make easy patient remain effective patient forever disease maintain treatment regime gsk progress patient combine number novel diabete drug clinical trial ongoing different drug research programme metabolic research centre beecham focus research treatment north carolina new mechanism combat insulin resistance rapid increase obesity major cause type area little know take year diabetes appearance disease child research promise compound make research important identify team develop novel ethical conduct introduction access medicine research ethical conduct code conduct marketing ethic marketing code practice consumer advertising training awareness monitor compliance employment practice human right environment community investment datum summary gsk corporate responsibility report ethical conduct gsk fully commit ensure business practice meet high standard ethic legal compliance employee behave honesty integrity important right way conduct business affect patient consumer use product doctor prescribe medicine government regulate industry reputation reputation stakeholder critical business reputation affect ability attract retain motivate good people meet high ethical standard enable maintain support stakeholder retain licence operate section explain approach business code conduct marketing ethic performance cover employee guide business conduct set gsk code conduct management certification standard behaviour expect employee business ethic key compliance ethic policy guide business activity require employee act approach marketing ethic include integrity comply law avoid conflict interest marketing code practice update policy report violation law gsk policy directtoconsumer advertise unethical behaviour training awareness programme reinforce guidance provide include reallife example importance ethical conduct ensure constitute acceptable unacceptable behaviour employee understand standard behaviour gsk employee access guide company require intranet induction training familiarise new monitoring compliance system include role employee business conduct standard provide corporate ethic compliance department information obtain support channel receive report allege case answer question misconduct datum number employee management certification business ethic dismiss disciplined violate company policy include code conduct commitment code conduct reinforce annual management certification programme information ethical issue available require manager certify comply research section report include policy statement expand programme govern relationship doctor involve clinical include manager worldwide eligible trial conduct clinical trial policy manager business unit worldwide disclosure clinical trial result write article complete certification certification documentation medical journal clinical trial information result manage electronically noncertification track information relationship government follow noncertification typically available section government external extended leave absence maternity leave affair policy make product longterm sick leave widely available access medicine background information ethic policy available website gsk corporate responsibility report ethical conduct continue certification statement reproduce market france germany belgium link include statement certification process slightly different accessible internal intranet code reflect local legal requirement conduct employee guide business conduct business ethic supplier document available responsibility section gsk produce booklet help supplier wwwgskcom understand requirement meet order work gsk booklet outline importance gsk place operate high ethical standard certify include reference gsk policy gsk understand gsk commit employee bind prohibit acceptance principle performance integrity gift entertainment working gsk supplier particular ensuring activity comply ask understand respect position applicable law supplier gsk ask adopt follow high standard business receive copy access interaction gsk gsk code conduct polgsk gsk corporate policy corporate policy index link intranet site marketing ethic read understand employee gsk market medicine doctor hospital guide business conduct accessible link government countrie intranet site japan advertise medicine directly consumer comply applicable law specialist sale representative meet regularly regulation gsk corporate local doctor pharmacist inform policy procedure medicine approve use people supervision receive believe sale representative play copy access gsk code important role provide uptodate information conduct gsk policy doctor product benefit patient inform responsibility recognise marketing pharmaceutical product raise challenge issue place appropriate measure particular people concern marketing ensure people supervision pharmaceutical company exert undue influence comply law regulation gsk doctor sale representative corporate local policy procedure doctor information potential effect work behalf gsk promotion unapproved use common understand responsibility promptly despite increase compliance training monitoring report actual suspect violation activity oversight government law regulation gsk corporate local sale promotion pharmaceutical product policy procedure highly regulate government medical agency report actual potential government extend legislation area compliance issue aware instance propose law concern legal requirement company pende state legislature require policy pharmaceutical company restrict report interaction doctor exception list compliance issue report previously gsk employee comply marketing code practice policy govern consumer advertising code require marketing base valid scientific evidence consistent national prescribing documentation comply law gsk corporate responsibility report ethical conduct continue update strengthen appropriate hospitality meeting entertainment policy procedure permit hospitality travel cost food provide meeting educational sale marketing employee receive training ensure purpose level hospitality appropriate good understanding marketing policy occasion provide relevant legal framework govern sale activity healthcare professional spouse child office program monitor compliance personnel guest travel cost include region feedback doctor provide sale practice regional code available local gsk rate survey french doctor language employee access conduct insemma marketing research institute intranet sale marketing staff receive training assess pharmaceutical company comply code training awareness industry marketing code copy gsk european promotion medicine doctor notice gsk take leadership code practice available online report stance area gift entertainment particular reaction vary gsk set good progress example industry follow gsk president pharmaceutical operation majority reaction pay spouse direct report conduct review regional travel ill company marketing code confirm gsk code minority reaction particular case comprehensive consistently apply region recently gsk offer sponsor doctor attend identify certain area improvement congress ask gsk pay wife update code accordingly change accompany congress gsk manager include reduce maximum value nominal gift refuse request contrary marketing healthcare professional code practice doctor sponsor prohibit gift entertainment medical company attend congress professional retain consultant gsk ensure decision grant medical education marketing code practice donation charitable purpose review pharmaceutical marketing promotional activity department independent sale marketing policy apply employee agent commit promotional practice ethical responsible launch new procedure europe sponsor principle patientcentred prohibit kickback attendance doctor medical conference bribery inducement doctor procedure specifie circumstance sponsorship appropriate govern provision policy support regional marketing practice appropriate travel meal accommodation code europe international region japan code apply ethical standard compliance policy procedure formal reflect difference market structure national healthcare performance objective sale marketing employee system regulation incorporate principle evaluate employee industry code practice efpia ifpma performance review encourage employee view jpma phrma marketing code compliance integral overall performance employee pharmaceutical business code explain policy issue appraise follow objective provide accurate information information consistently follow company policy provide approve use medicine procedure complete require compliance information accurate balanced fair objective training timely manner report compliance unambiguous uptodate issue manager legal compliance gift healthcare professional gift give occasionally relevant practice medicine gift inducement prescribe medicine gsk corporate responsibility report ethical conduct continue addition manager evaluate follow design educate consumer medicine objective condition prescribe dtc advertising pharmaceutical accurate support ensure supervised employee train evidence include information risk company policy procedure take benefit treatment option diet require training provide oversight lifestyle change principle available direction supervise employee wwwphrmaorg compliance company policy procedure gsk early supporter new principle consumer advertising review update marketing policy section explain approach advertising incorporate phrma guide principle prescription medicine advertise additional requirement ensure compliance consumer healthcare product market new provision implement update directtoconsumer advertising dtc policy include advertise prescription medicine elimination reminder advertisement short consumer print advertisement advertisement mention pharmaceutical know directtoconsumer dtc advertising dtc brand medical condition advertising permit market design treat new zealand bangladesh korea allow submission new television ad fda review limited dtc advertising day advance stage promote use prescription drug directly development audio visual component consumer controversial critic believe areavailable encourage people request unnecessary treatment provide information treatment option add burden healthcaresystem diet lifestyle change advertise believe responsible pharmaceutical advertising condition treatment option reference useful source health information patient prescribe information product help increase awareness condition patient require reference phrmas partnership appreciate know educate prescription assistance brand print ad patient treatment option patient brand website programme direct patient consult physician condition member company low income patient assistance appropriateness prescription medicine obtain program consent receive medicine country wheredtc advertising marketing practice nonpharmaceutical common industry practice need ensure product product promote way advertise overthecounter medicine oral healthcareproduct nutritional product bangladesh run dtc campaign vaccine consumer worldwide advertising govern include television commercial newspaper national regulation code practice advertising advertisement campaign title vaccination internal policy procedure meet exceed run period year local law international commercial excellence exchange award internal gsk awardand approve advertising consumer healthcare medicine local regulatory authority nutritional generally subject stringent directto consumer advertising requirement prescription pharmaceutical industry association medicine gsk consumer healthcare global phrma introduce new guiding principle dtc advertising guideline require claim advertising prescription medicine consumer healthcaremedicine advertisement launch january consistent product labelling market allow principle state company spend comparative advertisement gsk consumer healthcare appropriate time educate doctor guideline require comparison gsk product healthcare professional new drug acompetitorsbe support adequate datum consumer advertising begin advertise previous version report incorrectly state advertise prescription medicine consumer japan advertising prescription medicine consumer illegal japan advertise prescription medicine consumer japan run dtc advertisment raise awareness disease patient general public mention prescription brand gsk corporate responsibility report ethical conduct continue concern advertising food train new sale marketing employee cover drink contribute rise childhood obesity marketing code practice induction course government health select committee ensure new employee understand importance recommendation tackle obesity include ethical conduct day know deal restriction advertise child placement dilemma seek help vend machine school provide additional training employee gsk consumer healthcare guideline advertising working area additional regulatory child meet exceed local law code requirement manufacturing sale practice guideline advertising child prohibit marketing drug advertising design appeal target sale representative receive detailed training child legally mandate minimum age medicine promote disease example buy advertising space design treat sale employee give training children medium supply vend machine appropriate marketing practice require pass primary school test marketing code start sale role sport star sponsorship important brand regular refresher course hold sale lucozade sport guideline sponsorship state marketing employee annually example people set appropriate example market employee look example ethical sponsorship appeal dilemma issue face work solely child age guidance provide help understand advertising overthecounter medicine appropriate response employee encourage ask comply governmental advertising guideline follow question make advertiser reasonable basis make claim decision publish comparative advertising overthe embarrassed friend family know counter medicine permit long decision claim truthful mislead consumer testimonial celebrity endorsement permit decision look cynic long statement reflect honest opinion newspaper headline look like speaker true deceptive confident right decision gsk consumer healthcare member gsk consumer healthcare product association chpa monitor success training awareness voluntary code advertising practice programme example conduct survey nonprescription medicine guideline advise gsk sale representative survey reveal practice advertising imply casual attitude drug suggest overthecounter drug prevent cure disease employee rate effort promote treat licensed practitioner gsk consumer compliance effective healthcare advertising review ensure meet representative correctly answer government industry standard question promotional material sample management policy train awareness employee suggest solution handle compliance challenge train awareness programme sure employee understand policy comply conduct global management survey law know standard behaviour require year survey show manager say understand gsk code conduct training start induction course new applied job employee cover gsk code conduct relevant policy induction gsk corporate responsibility report ethical conduct continue activity monitoring compliance launch new half day workshop ethical recognise strong policy code practice decision making attend good training guarantee employee senior manager include staff meet standard internal compliance system corporate function finance design identify address breach code communication workshop give participant section cover practical tool help make ethical decision highlight manager obligation employee role corporate ethic compliance guide business conduct risk associate department noncompliance channel employee report concern manager attend ethical decision suspect case misconduct number type making workshop choose attend recognise contact channel need involve engage manager address misconduct number employee gsk ongoing basis dismiss discipline misconduct launch additional ethic elearne facetoface training package manager corporate ethic compliance function corporate ethic compliance department work new sale marketing staff gsk business unit promote effective risk receive training compliance policy management compliance programme identify exist staff receive hour annual address compliance issue ensure appropriate refresher training track sale oversight upward reporting gsk senior marketing training hour country anther management board dedicate initiative improve employee understand yearly fulltime compliance officer seven major bulletin launch pharma compliance office business unit manufacturing biological pharma major type unethical conduct detect europe international pharma japan pharma action take pharma addition corporate compliance officer employee complete perform report directly ceo integrity course course compliance officer senior manager direct access establish leadership team gsk function employee complete course include training source expertise question ethic code conduct policy conflict compliance gsk policy compliance officer interest acceptance gift entertainment define training need communicate late gsk employee development new policy legislation affect objective gsk deliver training assess compliance review performance integrity facetoface issue business unit market appoint induction training session appropriate local compliance champion change new staff appoint compliance staff sale marketing compliance adviser role launch additional ethic elearne facetoface provide feedback infraction conduct customise training package build ethical decision training recommend process improvement make workshop manager hire train staff new compliance datum analysis reporting group group begin analyse monitor investigation datum highlight suitable area focus follow business unit gsk corporate responsibility report ethical conduct continue sale representative supervise sale manager doctor raise concern report unethical regularly monitor educational event visits conduct gsk sale representative doctor expense independent customer response centre market research monitor review record number key risk area industry association phrma abpi internal audit department continue deploy staff retrain deal concern market significant resource provide regular audits business practice raise healthcare professional process include audit sale marketing patient public redirect call appropriate practice globally result audit finding senior management compliance officer necessary decision make process grant donation address misconduct update europe international region corporate ethic compliance department decision relevant medical monitor track allegation suspect case department instead commercial staff legal ethical policy infraction ensure european code marketing practice include allegation appropriately investigate disciplinary quarterly reporting mechanism market confirm action include dismissal take breach code practice necessary occur severity breach action take prevent recurrence report review senior manager similar procedure employee discipline misconduct monitoring expense launch compare highlight inconsistency country dismiss agree leave area improvement country company voluntarily compare european region receive central direction monitoring expense relevant disciplinary action include verbal write expenditure warning instance financial penalty employee stay company receive reporting channel train increase monitor employee encourage seek help report number increase believe concern suspect case misconduct probably well report breach people line management compliance officer familiar report confidential integrity helpline offsite anticipate number continue post office box increase detection report helpline post office box promote mechanism refine employee guide business conduct gsk disciplinary action include case intranet train corporate ethic employee breach sale marketing code compliance function promote source case result dismissal separation information advice mechanism company verbal warning report concern write warning include small spend allow limit hospitality scientific meeting contact compliance function mainly increase year employee seek advice information employee report suspect case misconduct outside mechanism track information evolve general trend issue visible senior management address action necessary employment practice introduction access medicine research ethical conduct employment practice employee survey diversity employee development talent management internal communication health safety manage health safety injury illness rate cause incident fatality employee health safety programme human right environment community investment datum summary gsk corporate responsibility report employment practice gsk employ people country goal good place good people well work central business strategy key business success aim create positive work environment offer competitive reward package emphasise performance provide opportunity training advancement listen respond employee feedback annual report detail business strategy expect employee meet high standard way conduct global leadership survey year carry work gsk gsk spirit define manager take survey culture principle expect employee result show significant improvement work item compare result detail result corporate responsibility report performance integrity survey finding review gsk corporate executive entrepreneurial spirit team business unit implement action focus innovation plan deliver improvement key area example gms extend core leadership edge programme sense urgency leader increase focus staff passion achievement development include mentor coach implement quarterly pulse employee regular performance appraisal assess employee survey understand well opportunity uphold principle requirement enhance employee engagement satisfaction code conduct work ethical conduct launch focus patient initiative code result affect bonus career build strength put patient progression plan decision make section explain approach performance activity cover conduct range interim employee survey gauge regular employee survey satisfaction motivation engagement programme recruit retain diverse leadership survey workforce annual inclusion resilience poll send employee development performance appraisal employee survey gather talent management feedback worklife resilience issue progress diversity vision score communicate employee diversity high result include feedback health safety wellbee programme favourable question employee survey rate overall sustainability business rest factor satisfaction gsk difficult measure quality leadership present time culture ability develop talented people regular employee survey help monitor evolution feel value employee gsk gsk culture overall employee satisfaction manager enable flexible result assess effectiveness people innovative solution manage management practice identify area work personal life improvement work environment enable maintain healthy lifestyle gsk corporate responsibility report employment practice continue diversity gender diversity worldwide gsk commit employ diverse workforce woman management position hold environment employee treat respect grade woman dignity diversity benefit business workforce diverse background culture outlook help band understand need different patient customer deliver genuine equality opportunity sure good people right job good work gsk total management grade range initiative ensure meet corporate executive team senior vice president vice president diversity commitment monitor report datum director level gender diversity management grade worldwide manager level ethnicity background information website woman remain underrepresented senior grade continue focus way ensure woman activity performance genuine equality opportunity gsk annual inclusion resilience poll include hold woman science event year question diversity rate high enable female science graduate feedback gsk attract woman scientist similar respondent agree senior management event launch attend show action create inclusive female male employee focus environment priority gsk compare development woman scientist gsk think workgroup climate diverse perspective value compare thought manager demonstrate ability manage diverse workgroup compare gsk receive score corporate equality human right campaign foundation measure company treatment gay lesbian bisexual transgender employee consumer investor company scoring percent include organisation good place work glbt equality list gsk corporate responsibility report employment practice continue ethnic diversity people color employee people color employee population ethnic minority employee employee ethnic minority gsk corporate responsibility report employment practice continue people colour employee development talent workforce compare management ethnic minority define commission gsk invest train development enable racial equality account employee employee perform good ability compare report develop career talent management process wrongly report number ethnic minority help identify develop leadership candidate employee error datum collection system correct training provide jobrelate training course employee multicultural marketing diversity award leadership training manager employee enrol annual multicultural marketing diversity award train programme mylearne intranet recognise staff find creative way reach site employee wide audience employee customer attend development programme community award give category country similar opportunity exist employee include employee attraction development worldwide datum currently collect retention year winner include takeup programme residential chemistry training experience people attend leadership edge global design increase diversity candidate programme senior manager attend attract chemistry role final year undergraduate leadershipgsk programme middle manager spend week gsk programme run inspirational leadership workshop attend application particularly seek ethnic executive senior leader significant minority student nontraditional university influence large number staff focus gsk recruit participant receive coach senior leadership role inspire motivate people technical personal professional subject high performance meet business challenge interact gsk employee level employee attend foundation niquitinteam birmingham raise programme new manager managementgsk awareness smoking cessation ethnic programme design help manager improve population high average smoking performance staff increase insight rate differ work style strength motivation consumer healthcare hispanic employee development network work number gsk brand regular performance appraisal reward strong help understand improve appeal performance help employee set objective hispanic community include sensodyne identify training need twothird brand network input increase sale gsk employee receive annual performance appraisal hispanic community compare performance development planning general market increase pdp programme employee network pdp include assessment employee employee network include programme asian implement gsk spirit principle use african american hispanic gay lesbian employee define culture significant impact provide forum employee similar bonus payment potentially reduce zero background meet discuss issue share concern employee find follow spirit set gay lesbian staff network affect future career development simple reason enable positive inclusion lesbian gay talent management transsexual staff gsk culture team work identify high perform employee essential requirement modern pharmaceutical business function annual talent industry exclusion ground sexuality sexual management cycle talented individual orientation obstacle effective team work leadership programme expose personal development management programme chief chair founder gsk glsn executive forum gsk corporate responsibility report employment practice continue pool potential successor identify vice consult employee change affect president senior management position discuss business development work review annually appointment subcommittee council european employee forum board similar forum country national practice european employee forum internal communication discuss topic include transformation optimisation programme europe proposal good internal communication important achieve change gsk european distribution supply business objective create open chain company approach stress inclusive work environment range workplace new information consultation communication channel employee date forum establish address company news enable feedback strategic level business development company include proposal change area employment mygsk global intranet site provide news policy pension update section employee townhall session employee level question directly ceo senior company host senior management executive garni gsk chief executive employee opportunity discuss progress answer question news section business raise question feedback gsk intranet give company position important issue link press story gsk employee inform corporate mygsk update ensure responsibility copy employees access news policy overview brochure distribute employee directly spirit magazine online survey webbroadcast gsk senior management send randomly select gsk employee assess include executive team member awareness approach reporting employee major site february gsk ceo stakeholder feedback chairman head host global broadcast view employee site develop internal communication initiative employee complete followup survey ethical leadership role employee agree broadcast increase protect enhance gsk reputation understand gsk priority launch include elearne module second broadcast december celebrate year guidance manager facilitate discussion gsk vaccine show venue ethic policy team new material recognise employee outstanding mygsk contribution company track effectiveness communication spirit internal magazine reach questionnaire employee survey monitor employee company time year question employee senior manager site produce local newsletter page mygsk ensure pick potential confidential feedback mechanism enable employee area concern track readership news story raise concern include integrity helpline mygsk help improve relevance interest ethical conduct content employee survey carry regularly organisation employee survey conduct biannual leadership survey gsk corporate responsibility report employment practice continue health safety consumer research development site seven distribution centre major office location health safety employee contractor approximately small office sale absolute priority gsk programme location include available data site systematically assess risk associate operation year note attach operation monitor performance cause chart explain scope datum collection process incident aim assess learn parameter detail include datum action protect employee workplace injury illness number supplier need improve implementation site provide information aim eliminate workrelate injury verification illness main measure number case result time work losttime case target environment health safety section year reduce number report externally verify erm hour work year achieve environmental resource management target average year rate web page verification apply remain constant indicate symbol erm verification meet fiveyear target statement set new target manage health safety plan excellence set target manage health safety integrate reportable case gsk define environment health safety ehs management aid report system system incorporate ehs employee government regulation country safety theory health policy eh vision global ehs standard suggest address reportable help ehs plan excellence set strategy eliminate risk hazard lead fewer improve ehs performance currently reportable case losttime case renew extend health safety section corporate environment health safety cehs report employee health management ehm team help section contain information manage coordinate health safety programme health safety overall ehs management page summarise activity describe programme report injury illness relate specifically health safety ehs rate highlight incident fatality cover management page information manage health safety audits gsk operation environmental broad ehs issue programme cover wide range aspect training awareness provide safety training sale employee tend ehs train target match employee high number fatality work responsibility employee responsibility employee improve general health issue receive regular training initiative area year report health ergonomic chemical exposure driver safety safety performance legacy company glaxo handle regional meeting staff wellcome smithkline beecham individually publish turn train employee manufacture research ehs report number year prior formation sale division cehs ehm arrange annual gsk copy report available meeting determine training issue provide corporate register website training material wwwcorporateregistercom want employee aware health scope datum safety personal life employee bulletin health safety data cover calendar year announcement myehs website ceo ehs collect pharmaceutical excellence awards programme health safety consumer manufacturing site seven biological week activity aim raise employee awareness issue manufacture site pharmaceutical wear seat belt careful electricity ladder appropriately gsk corporate responsibility report employment practice continue conduct health safety week october introduce continued specific work coincide european health safety week follow area achieve improvement fire safety awareness month united states chemical agent target set manufacture information kit send site help develop promote accurate exposure determination idea plan activity ensure adequacy respiratory protective employee site equipment unit operation discussion country take health safety week presentation network meeting activity include sport day safe drive education resilience rollout tool assess team ergonomic training awarenessraising noise resilience training ehs network meeting safeguard hear healthy eat lifestyle family participation event ergonomic train ergonomic risk assessment network meeting regional training health safety feedback ehs audits risk assessment guideline revise aim conduct ehs audits operational site align risk assessment requirement year carry frequent quality group visit select site depend assessment risk issue raise previous audits self audit train workshop selfauditing conduct ehs network meeting end assess performance facility small commercial site self management system element rollout assessment internal audit audit site management system toolkit describe average score site achieve score site require develop plan address regard unacceptable weakness potential improvement identify average score exceed target aim audit auditor monitor site progress correct unacceptable performance continue pursue implement plan auditor train improvement achieve good practice finding compare ensure consistency continue refine ehs audit process scoring audits identify priority area system base experience feedback chemical exposure risk instal ehs auditing software intranet help chemical risk assessment control site auditor track progress manage resilience mental wellbeing ohsa certification additional site achieve certification ergonomic risk assessment control international health safety standard ohsa scope adequacy workplace risk assessment bring total number manufacture site selfaudite health safety programme certify pharmaceutical consumer vaccine manufacture site additional site management system implementation certify utility area certify site aim drive improvement poorlyperforme area china egypt france india kenya mexico poland saudi actively track audit finding identify arabia turkey audits certification improvement followup audits site score information certification environmental provide increase support management standard iso audit team include followup visit ensure progress discussion senior business management increase site resource site require year adequate system programme place area gsk corporate responsibility report employment practice continue excellence awards drum solvent year reduce risk chief executive officer environment health solvent spill reduce cleaning safety ehs excellence awards recognise reward disposal requirement waste drum pallet innovation gsk site win entry musculoskeletal injury report ehs initiative health safety category incident involve chemical burn solvent splash time metering system introduce placebarnard castle prove capability award give shirt sleeve working environment ceo ehs excellence award website site move control operator exposure award programme winner previous highly potent compound containment year routine task respiratory protective equipment guard exposure ehs consideration injury illness rate cause integrate site business model main measure injury illness number introduce new product allow incident result day away containment integrate design work lose time express rate manufacture hour work second placewavre belgium sobane target reduce losttime rate innovative approach safety year end fact rate improve suggest reach wavre introduce new approach safety management plateau effectiveness prevention significantly reduce number programme injury gsk biological site belgium involve research development production renew effort improve effectiveness vaccine programme focus reportable injury illness result time work site speciallydesigne build reportable incident aid employee work fill vial syrinx result day work safety vaccine seven losttime injury expert believe address cause build week injury result improvement accident result disability type category injury sustain get significantly bad ehs department respond introduce new safety measure number day lose injury management methodology know sobane illness provide indication severity incident rough guide sobane method involve active participation example illness lead permanent hearing loss staff screen potential safety risk find disability result significant lose time solution member staff member team active safety role main data cover gsk employee contract worker directly supervise separately report method introduce resulted datum contractor work gsk site supervise potential safety risk solve staff staff datum cover erm lost verification time injury day pass accident result disability cause injury illnesse injury lose time arise mainly slip method expand gsk biological trip fall overexertion strain motor vehicle site belgium plan introduce gsk accident biological site world losttime illness stem mainly mental illhealth placecork ireland bulk solvent metering musculoskeletal problem primarily repetitive strain injury research development pilot plant musculoskeletal illness main cause reportable introduction bulk solvent metering cork illness lead day work accounting pilot plant eliminate need handle total gsk corporate responsibility report employment practice continue mental illhealth approximately illnesse result case workrelate mental ill health exclude permanent disability noiseinduce hearing overall illness rate consistency loss sensitisation chemical musculoskeletal reporting case robust occupational illness illnesse variation way illnesses gsk injury illness performance place define local legislation affect report quartile benchmark industry group working address inconsistency aim include case future mental ill cause injury illnesse health rate involve lose time main cause injury motor vehicle accident hour work mental illhealth second slip trip fall illness lead lose time significant cause workrelate sickness absence mainly musculoskeletal concerned mental ill accounting day total health chemicalrelate dermatitis follow exposure chemical work cause significant number illnesse information programme reduce illness lead lose time injury health programme safety programme record highlight workplace injury illness incident site country lose time injury illnesse year addition gsk employee contractor site india achieve million hour work injury illnesse lose time injury illness incident lead site singapore achieve million hour work lose time lose time injury illness musculoskeletal site canada china india pakistan achieve include million hour work lose time injury mental illness illness include fourteen site china france india mexico pakistan day lose philippines south africa achieve exclude mental illness million hour work lose time injury illness reportable incident performance lead lose time table summarise experience chart illustrate trend musculoskeletal include record injury illness compare respectively mental illness employee lose working day incident include compare record expect relationship incident result lose time contractor datum include verification erm suggest undercount real number injury illness result lose time work improve report injury illnesse gsk corporate responsibility report employment practice continue lose time injury illness rate injury illness lose time injury illness rate year illness injury total dekrow sruoh rep gsk corporate responsibility report employment practice continue reportable injury illness lost time rate injury illness dekrow sruoh rep reportable injury illness lost time rate year illness injury total gsk corporate responsibility report employment practice continue lose time injury illness business primary tibiotics product supply egional pharma supply umer healthcare supply biological researc ven opment commercial lose time injury illness business rate primary supply antibiotic new product global supply regional pharma supply consumer healthcare supply biological research development commercial dekrow sruoh rep gsk corporate responsibility report employment practice continue reportable injury illness lost time business primary tibiotics product supply egional pharma supply umer healthcare supply biological researc ven opment commercial reportable injury illness lost time business rate primary supply antibiotic new product global supply regional pharma supply consumer healthcare supply biological research development commercial dekrow sruoh rep gsk corporate responsibility report employment practice continue calendar day lose rate injury illness calendar day lose rate year illness injury total dekrow sruoh rep gsk corporate responsibility report employment practice continue category lose time injury contact sharp object catch inonbetween slipstripsfall strike againststruck overexertionsstrain motor vehicle accident slipstripsfall motor vehicle accident overexertionsstrains strike againststruck catch inonbetween contact sharp object burnsthermalchemical foreign bodiesobject workplace violence electricalfireexplosion animalinsect total gsk corporate responsibility report employment practice continue category lose time illness infection musculoskeletal mental health musculoskeletal mental health infection nonallergic respiratory allergic respiratory nonallergic dermal systemic allergic dermal physical cancer reproductive total gsk corporate responsibility report employment practice continue category reportable injury lose time overexertionsstrain burnsthermalchemical catch inonbetween slipstripsfall motor vehicle accident strike againststruck contact sharp object overexertionsstrain slipstripsfall strike againststruck contact sharp object motor vehicle accident catch inonbetween burnsthermalchemical animalinsect foreign bodiesobject electricalfireexplosion workplace violence total gsk corporate responsibility report employment practice continue category reportable illness lose time mental health allergic respiratory infection nonallergic respiratory musculoskeletal allergic dermal physical nonallergic dermal musculoskeletal nonallergic dermal physical allergic dermal nonallergic respiratory infection allergic respiratory mental health systemic cancer reproductive total gsk corporate responsibility report employment practice continue summary table lose time injury illness lose time injury lose time injury illness lose time rate illness rate lose time injury illness year injury illness hour work injury illness lose time injury lose time illness lose time injury illnesse lose time hour work calendar day lose injury illness lose day injury day lose illness calendar day lose hour work injury illnesse lose time rate year injury illness note chart health safety datum cover employee contract worker directly supervise gsk employee injury illness rate hour work lose time injury illnesse workrelate injury illnesse result day away work calendar day lose rate lost calendar day calendar day year injury illness employee work workrelate injury illness help provide measure severity injury illnesse reportable injury illnesse lose time report incident result time away work lose time aid generally lose time include case mental ill health lose time reportable illness rate supplier health safety performance variation way mental illhealth define report site globally work request information supplier address include contract manufacturer key supplier provide datum provide datum comparative figure supplier report total million work hour gsk corporate responsibility report employment practice continue incident fatality employee health deeply regret employee die work workplace culture support healthy resilient relate driving incident egypt member workforce drive positive business performance protect public kill drive accident promote wellbee employee increase involve gsk employee employee productivity attendance reduce health care health insurance cost support work reduce traffic relate accident goal employee choice align driver safety programme safety programme gsk mission improve quality life see reduction number workrelate section focus step fatality year consistent take improve ergonomic resilience manage target improve health safety performance set pressure stress attendance provide plan excellence contractor fatality information hiv initiative planning process remain largely constant period potential worldwide influenza pandemic year trend employee fatality health programme fatality health programme enable employee family benefit well health enhance quality life business gain increase employee commitment productivity reduction financial impact illhealth range programme support employee wellbee include onsite health fitness centre flexible working arrangement family support service healthcare benefit focus prevention report incident incident result access innovative prove treatment example permanent disability report employee receive free immunization cancer regulatory authority accident involve screening help smoke cessation regular check machinery result employee site south up assist employee suffer chronic disease africa puerto rico suffer finger medical plan provide support help amputation contract temporary worker site continue treatment low leg amputate result develop scorecard measure track forklift incident employee progress improve employee health add value evacuate site france follow accidental business scorecard contain quantitative release hazardous chemical need medical measure include illhealth absence rate report treatment hospitalise night performance measure target sale employee involve multi vehicle road accident result severe injury hospitalisation employee suffer burn hold workshop globally environment body result burst pipework release health safety human resource share boiling water steam information good practice employee health management department support site gsk investigate circumstance fatality implement employee health policy achieve incident assess learn consistent standard carry internal audits reduce risk issue global alert post monitor site performance oversee improvement plan intranet site communicate information help prevent similar incident site ergonomic musculoskeletal illness injury lead cause ill health result time away work appoint fulltime professional ergonomist lead development ergonomic strategy set target reduce number ergonomic gsk corporate responsibility report employment practice continue illness injury improve workplace team resilience programme participatory job design improve efficiency proactive quality improvement process utilize productivity assessment tool identify source workplace stress teambase solution focus process look internal ergonomic university establish issue cause pressure affect performance increase knowledge ergonomic issue work demand team relationship management good practice gsk employee introduce practice career development concern work computer presentation variety ergonomic topic culture individual team member confidential cdbase programme commercial fieldbase personal profile tailor action plan develop employee cover ergonomic global team staff take team ergonomic community website develop resilience programme programme employee discuss issue share idea access translate spanish portuguese french german resource include good practice example range italian japanese mandarin laptop ergonomic lift majority gsk site programme reduce launch online ergonomic risk assessment workplace pressure help employee achieve good officebased employee help reduce ergonomic injury worklife balance include time management associate computer use programme training flexible work option health awareness gsk site worldwide translate education initiative employee spanish french italian polish worldwide access employee assistance employee complete computerbase risk programme provide confidential support hour assessment develop similar risk assessment day additional counselling need tool nonoffice base employee pilot manufacturing site team resilience programme receive external recognition health safety executive establish employeele ergonomic hse nominate award improvement team manufacture site include win personnel todays manage health latin america role embe ergonomic work award design consideration workplace practice procedure example team zebulon site attendance number improvement work longterm employee absence financial impact environment include use adjustable height gsk lose productivity efficiency limit cart reduce injury lift heavy item employee absence help work return roll material reduce waste reduce soon appropriate minimise cost manual handling material launch improve employee wellbee ergonomic improvement team manufacture facility launch new case management approach europe asia longterm employee absence involve resilience close collaboration ehm team staff line mental illness lead cause manager employee key element ill health result time away work use include accurately measure absence ensure term resilience describe set skill behaviour maintain regular contact employee need successful highly pressured fastpaced work sure employee doctor continuously change environment enable know widerange inhouse support available support employee manage work home gsk include access physiotherapist counsellor demand effectively minimise adverse occupational health physicians health affect stress datum resilience rehabilitation plan agree employee programme improve business result include make modification workplace employee commitment engagement reduce work hour find alternative work programme fully support legislative fully recover requirement tackle source workplace stress gsk corporate responsibility report employment practice continue initial result suggest approach lead fall team develop global policy plan gsk absence rate site approximately business continuity employee health preparedness year estimate plan minimise impact pandemic manufacturing site experience cost saving employee ensure able continue million base direct indirect manufacturing medicine vaccine cost absence employee return work safety programme quickly sign long systematically assess risk anticipate potential necessary staff feedback indicate majority accident programme place minimise employee feel betterinformed value support learn investigate cause accident continue roll new improvement accordingly section procedure site plan cover key area driver safety process safety complete process mid target chemical exposure reduce number day lose longterm information approach ergonomic absence set target employee health manufacturing site worldwide achieve attendance driver safety sale representative drive long distance year hivaid particularly risk involve provide antiretroviral treatment arv hiv workrelate road traffic incident positive gsk employee parttime drive accident result lose time family develop world treatment account losttime injury provide adequately consistently local healthcare system global ehs standard occupational travel include requirement driver safety develop offer preferentially price arvs employer technical instruction document help gsk business subsaharan africa provide care treatment comply standard cover topic staff preferential pricing training vehicle selection risk assessment accident develop awarenessraising initiative use report drive environment worldwide educational material develop combine document additional safety gsk kenya positive action programme guideline create compliance tool commercial wwwgskcompositiveaction adopt business call ehs essential company kenya reach estimate approximately gsk commercial business employee public private sector material extensive driver safety programme place include translate french available drive licence check guidance use mobile company burkina faso cameroon chad gabon phone vehicle driver safety training tracking madagascar mali early material report incident work ensure site translate arabic help company high standard place morocco gsk mexico gsk dominican republic develop similar spanishlanguage resource use country provide motorbike scooter central america gsk india start process employee produce gsk motorbike rider employee workshop hiv aids safety manual translate distribute pilot survey demonstrate need employee employee country bangladesh india hiv education indonesia pakistan vietnam country fully implement gsk requirement influenza pandemic driver motorbike wear helmet global outbreak avian influenza bird flu continue follow monitor implementation highlight danger potential worldwide influenza motorbike safety programme pandemic externally work government assist provision development antiviral drug vaccine manage potential pandemic internally cross business gsk corporate responsibility report employment practice continue process safety safety engineering commission benchmarking study process safety programme ensure safety containment method potent chemical compound build manufacturing research development second member engineering staff process programme base hazard corporate ehs work ensure relevant identification control risk assessment operation engineering control expand risk assessment tool evaluation new product support process design rate system include tool cover failure integrate ehs consideration product design team mode effect analysis hazard operability failure include product stewardshipoccupational toxicology mode effect criticality analysis programme apply expert role ensure chemical exposure globally allow standardized assessment ehs consideration build product documentation share safety information design business sector launch initiative ensure primary supply antibiotic supply chain update safety plan focus key risk regulatory compliance material hazard information hazclass system track hazardous material shipment worldwide monitor transportation material month develop safety datum sheet sdss product pharmaceutical product sell europe available website wwwmsdsgskcom email notification tool automatically keep employee todate change sdss start environmental testing datum available sdss occupational hygiene control chemical exposure exposure chemical result respiratory skinrelate losttime incident case result lose time account workrelate illness develop strategy control chemical exposure set plan action achieve goal shirt sleeve work environment workplace contain chemical engineering control manufacture employee need wear protective equipment introduce step help achieve goal begin recruit regional hygienist deliver improve occupational hygiene service business begin design dispensary equipment powder pharmaceutical ingredient eliminate need protective equipment human right introduction access medicine research ethical conduct employment practice human right employee human right supply chain human right environment community investment datum summary gsk corporate responsibility report human right human right broad subject relevant gsk number different contexts section discuss human right gsk employee human right supply chain information preferential pricing arrangement hivaid medicine access medicine direct employee educate standard selfassessment questionnaire skilled people strive audit identify human right issue company attractive employer generally workforce employment standard issue diversity equal confirm gsk employ child opportunitie health safety provide adequate young employee entitle safeguard human right employee join trade union organise country supply chain complex diverse global permit national legislation commit recognise possible supplier country listen respond view employee fully respect human right worker include work council staff consultation local community sphere influence committee internal communication begin work ensure supplier observe discrimination harassment tolerate similar standard relation employee circumstance employee report concern community senior management confidential basis risk human right issue occur global integrity helpline case significant gsk company report employee compliance function industry reason directly raise human right issue need human right seriously achieve high standard human right support reputation supply chain human right goal operational excellence help good employee work supplier supply chain complex supplier match standard help ensure smooth worldwide range major strategic relationship operation supplier contract reliable supplier manufacture raw material supply high quality product packaging gsk medicine local contract good service office equipment clean security employee human right endeavour ensure supplier follow human right employee work protect high standard human right apply gsk employment policy procedure give size global scope supply chain detail employment recognise supplier fully respect operate globally include country human right worker local community government fully respect human right start work supplier issue believe presence country vital ensure inclusion human right clause supplier continue access medicine people aim contract create workplace employee country standard match operation cover human right issue routine contribute improve interaction category critical supplier employment practice generally contract manufacturer gskbrande medicine consumer health product supplier raw conduct annual human right employment audit material packaging manufacturing site sure deliver commitment historically supplier tended base international human right standard head human europe north america grow trend resource country operate require source material area report gsk employment practice meet gsk corporate responsibility report human right continue world asia visit critical supplier regularly supplier provide good gsk review performance identify resolve brand product contract manufacturer raw issue include potential human right issue material packaging interaction include supplier provide human resource clean preassessment potential new critical supplier service security service contingent worker services questionnaire onsite review quality outsource service test research development ehs audits assessment cover facility service directly supply gsk scope eventually extend contract ongoing critical supplier review include followup engagement critical supplier visit procurement quality ehs staff hold global regional supplier review meeting critical supplier work high quality senior gsk manager address interact standard produce uninterrupted supply supplier key issue material service gsk safety effectiveness availability medicine important procurement team understand affected reason seek longterm human right standard provide training relationship critical supplier regularly monitor guidance human right gsk procurement staff aspect performance include human right source group management programme explain develop source strategy critical supplier pass detailed assessment criterion supplier selection include human right select look quality issue train compulsory new procurement staff assess policy procedure health safety human right environmental issue give size complexity supply base rigorous assessment reduce risk issue possible engage directly supplier non compliance contract sign human right routine engagement supplier meet require standard critical supplier start pilot project work agree remedial programme assess risk human right issue occur implement complete award supplier service large labour input new business contract manufacturer example clean security approve applicable regulatory authority engage supplier environmental health start manufacture gsk medicine safety issue environment work contract award seek ribena supplier improve biodiversity develop strong open relationship critical supplier supplier contract includes formally agree supplier review add human right clause supplier assess performance identify agree area contract require supplier confirm improvement supplier review agree action comply minimum wage legislation provide healthy plan sign gsk supplier safe workplace free discrimination use supplier improve performance form slavery exploitative child labour business alternative supplier far incorporate human right clause launch preferred global vendor programme central contract template use new supplier reduce number supplier reduce human right clause introduce cost increase efficiency easy contract exist supplier renew monitor influence supplier standard contract renew threeyear cycle supplier audits work local procurement conduct regular environment health safety team incorporate human right clause local audits contract manufacturer include supplier contract give size supply chain question human right prioritise contract human right audits conduct human right issue clause insert initial focus significant concern note gsk corporate responsibility report human right continue gsk supplier human right clause human right clause base international workplace norm international labour organisation convention un universal declaration human right text set standard englishlanguage version contract clause note exact wording vary contract gsk attorney amend word clause negotiation party translation suit local law gsk attorney instruct change human right clause way reduce contractual impact intent gsk standard contract clause ethical standard human right ethical standard human right require prohibit law pay employee minimum wage supplier warrant good knowledge fair representation prevail industry relation supply good service wage whichever higher provide term agreement employee legally mandate benefit ait employ engage use git complie law work hour child labour circumstance task employment right country perform child labour operate reasonably foresee cause physical hit respectful employee right join emotional impairment development form independent trade union freedom child association bit use force labour form supplier agree responsible control prison indenture bond supply chain shall encourage employee require lodge paper compliance ethical standard human right deposit start work subsequent supplier good service provide safe healthy workplace supplier perform obligation present immediate hazard employee agreement housing provide supplier supplier shall ensure ethical employee safe habitation supplier human right policy appropriate complaint provide access clean water food procedure deal breach policy emergency healthcare employee event accident incident supplier gsk reserve right reasonable notice workplace inspection cause case notice shall necessary enter supplier premise dit discriminate employee monitor compliance supplier warranty ground include race religion disability set clause supplier shall gender subject compliance law furnish gsk eit engage support use relevant document request gsk relation corporal punishment mental physical sexual thereto subsection require verbal abuse use cruel abusive general right audit disciplinary practice workplace agreement environment introduction energy global warming potential energy consumption access medicine transport research water water use ethical conduct wastewater employment practice waste human right hazardous waste nonhazardous waste environment recycle introduction nonroutine waste erm verification statement ozone depletion gsk response ozonedeplete substance environmental management manufacturing plan excellence ozonedeplete substance audits certification ancillary equipment stakeholder engagement volatile organic compound train awareness biodiversity ehs excellence awards supplier progress target material efficiency community investment product stewardship datum summary product design pharmaceutical environment meter dose inhaler gsk corporate responsibility report environment year complete year environment health safety ehs plan excellence mark important milestone journey environmental sustainability environmental performance report page health safety performance report employee section introduction ehs structure include set stretch target consultation management system base set global business address ehs issue concern standard incorporate framework ehs stakeholder set target identify programme propose improvement project help ehs plan excellence identifie achieve specific underpinning tenyear strategic vision ehs gsk project achieve environmental target ceo ehs excellence awards recognise performance outstanding project gsk site world achieve ehs target meet link excellence awards document surpass target energy consumption relate carbon dioxide emission water consumption feel significant progress wastewater organic material measure chemical improve performance ehs gsk realise oxygen demand nonhazardous waste ozone need embed deplete substance produce inhaler culture people understand business benefit good ehs practice enhance productivity volatile organic compound voc emission air quality employee relationship beneficial achieve significant reduction achieve gsk performance reputation ambitious target reduction investor set ambitious target ozone deplete understand investor appreciate compound ancillary equipment achieve progress transparency mean improvement open area case change business help plan progress wastewater quality emission solvent borne positive rating gsk air case hazardous waste disposal receive investor rating recycling change progress difficult meet target area factor gsk recognize index maintenance recycling system movement product dow jones sustainability index djsi production facility recycle equipment djsi member cent industry new product introduction sector select large provide detail performance area company world selection base good performance page section inclass approach cover economic social environmental criterion eh management solid foundation programme management business environment index premier league system contribute progress gsk consecutive year gsk move describe selfregulatory list premier league achieve score ehs culture focus achieve legal cent data index rate environmental compliance manage ehs proactively base management environmental performance understand risk liability opportunitie carbon disclosure project climate leadership strategic objective achieve operational indexgsk pharmaceutical excellence responsible company company name climate leadership index carbon disclosure project coalition gsk corporate responsibility report environment continue institutional investor trillion energy conservation asset climate leadership index include long term possible step company position respond environmentally sustainable business financial implication climate change compare peer improve natural resource efficiency decrease waste generate look ftsegood ftsegood index series broadly production include efficiency include company meet globally recognise operation link material efficiency corporate responsibility standard facilitate investment company rely nonrenewable chemical renewable material sustainable companiesgsk pharmaceutical company identify synthetic chemical route biological global sustainable corporation system create medicine world project initiate corporate knight year achieve transition innov strategic value advisor lead journey environmentally research firm specialise analyse non traditional sustainable company driver risk shareholder value cover performance social environmental strategic james hagan governance issue launch annual vice president global announce year world corporate environment health safety economic forum davos environment section report rating like help investor identify company year report meet investment goal important environmental performance legacy company glaxo gsk reputation achieve proactive wellcome smithkline beecham individually publish approach eh sustainability companywide ehs report number year prior formation report ehs performance datum index listing gsk copy report available tribute ehs professional corporate register website manager staff gsk site report wwwcorporateregistercom datum list base background information approach investor stakeholder appreciate manage environmental issue available commitment dialogue appreciate environment health safety section website value stakeholder perspective wwwgskcom create formal stakeholder panel note scope datum consult widely gsk people environmental datum cover calendar year fiveyear plan period collect pharmaceutical future consumer manufacturing site biological internal external engagement help focus manufacture site pharmaceutical major challenge immediate future consumer research development site seven distribution centre major office occupational exposure chemical occupational location small office sale location hygiene include available data site operation driver safety year process safety note attach chart explain scope datum pharmaceutical environment collection process parameter detail specify unit sale figure absolute hazardous chemical usage number total consumption energy water etc gsk corporate responsibility report environment continue verification overall assessment environment health safety section subject scope assessment comment report externally verify erm environmental set believe gsk ehs report resource management page corporate responsibility report complete relevant verification apply indicate accurate representation gsk performance symbol erm verification statement review follow finding response follow recommendation finding erm verification statement report year gsk report progress environmental resource management limit erm year performance target set key area appoint gsk undertake external verification environment health safety find gsk assessment environment health safety ehs good progress strengthen internal reporting reporting gsk corporate responsibility process well understand reason ehs report section environment health performance change target safety page employee practice section gsk provide wide range information report fifth year involvement external clear material issue face verifi gsk objective assessment business find inconsistency level detail check ehs datum present accurate provide reason performance change example represent gsk performance fairly critically change major contribute site significantly review completeness relevance information affect group total present assess effectiveness gsk datum management reporting system page gsk gsk improve collection datum contract report contain ehs datum verify erm mark manufacturer supplier expand follow symbol number contract manufacturer collect key ehs datum ongoing challenge collect complete accurate datum gsk able report broad ehs footprint recommendation relate limitation ehs performance datum particular scope assessment potential scale statistical uncertainty period october february consideration gsk report conduct follow task consistently cover significance potential limitation assessment globally significant site datum calculation method robustness telephone interview additional site review sample technique understand performance eh data management reporting process change example calculate voc emission review corporate data collation internal data accuracy verification process gsk office gsk continue progress improve review content ehs section accuracy ehs datum introduce internal corporate responsibilityreport include check datum check globally significant site erm sample group datum assess completeness identify number material datum inaccuracy relevance accuracy assessment site level check sample group datum change report schedule interview corporate personnel obtain introduce meet deadline support information gsk ehs performance corporate reporting program inaccuracy follow area acquisition divestiture subsequently address gsk ensure accurate contaminate land auditing gsk site supplier report corporate responsibility report contract manufacturer report relate sale force set performance target gsk corporate responsibility report environment continue improvement energy performance gsk response verification statement follow introduction businessspecific energy verifying gsk ehs report year management programme help erm recommendation point improvement ensure accurate datum report gsk rolling work year example year improve new system function help integrate ehs management process collect datum clarify definition datum collection instruction provide training people site find challenge associate accurate gather enter site datum improve process complete health safety incident report analyse summarise datum try understand investigation site level include weakness formal change year year internal process check compliance gsk explain materiality requirement accurate reporting investigation planning process result incident addition find example year ehs plan excellence conduct misreporte poor understanding corporate review report consider measure report requirement datum entry error ehs impact company recommendation global reporting initiative survey investment recommend gsk rating organisation environmental organization indicator stakeholder expectation ehs reporting explain issue report material company size exercise business prioritise report accordingly conclude information metric include report trend outsource affect report material gsk decide overall eh footprint performance expand consistent reporting year period report ehs impact contract plan excellence manufacturer supplier year period review materiality information metric report continue improve accuracy environmental incident report external stakeholder consider datum introduce additional mechanism check important completeness datum report site provide additional training site report data trend outsource management goal report aggregate ehs review formal process check compliance performance contract manufacturer key gsk requirement accurate reporting supplier hope use report total ehs investigation incident footprint gsk product use basis improvement target request ehs look opportunity align datum information contract manufacturer management corporate site level integrate key supplier year response voluntary reporting core business process rate low intend response practicable questionnaire integral future contract erm accuracy site ehs data march comprehensive global ehs information management system place help site manage ehs datum use system collect datum report internal reporting recognise past error rate initial entry varie place thorough datum verification process correct error attempt address situation provide additional webbase training conduct formal review information request site simplify meet need stakeholder gsk corporate responsibility report environment continue review process check compliance stakeholder engagement play important role reporting investigation incident manage ehs carry special complete phase audit engagement exercise employee set programme conduct comprehensive baseline stand panel external ehs stakeholder feedback review start riskbase audit staff external source identifies issue process include review report ehs datum provide insight help determine investigation incident process forward increase level training area ceo ehs excellence awards recognise reward align corporate site datum management gsk site leadership ehs award conduct formal review highlight site demonstrate exceptional information management practice identify commitment innovative approach provide improvement example good practice ehs management share corporate site process site winner excellence award demonstrate project improve environmental performance save money environmental management carry regular ehs audits gsk operation environmental issue manage health contract manufacturer key supplier assess safety integrate ehs system aim extent management system standard ensure issue risk identify standard implement improve performance achieve establish training provide target set audits compliance conduct environment cost clearly define ehs management structure capital investment environmental project overall responsibility rest corporate executive million operating maintenance team board board champion ehs cost million expenditure relate garni chief executive officer rupert bondy general wastewater treatment waste management air counsel operational champion eh pollution control corporate executive team corporate responsibility committee corporate ehs department ehs management organisation system website ehs policy vision global ehs standard set overall framework manage issue distribute ehs management toolkit provide site instruction description appropriate procedure manager worldwide ehs plan excellence develop set year strategy improve environmental performance come end year period begin revise extend plan gsk corporate responsibility report environment continue waste wastewater air noillim capital investment capital investment year air wastewater waste total gsk corporate responsibility report environment continue operation maintenance cost waste wastewater air operation maintenance cost year air wastewater waste total noillim gsk corporate responsibility report environment continue compliance goal ensure core programme cover minimum aim comply legal health safety environment place requirement regret global business measure breach regulation case follow consumer healthcare manufacturing site pay implement operation ehs management fine court cost follow system align iso ohsa prosecution health safety executive incident occur result achieve acceptable audit score amputation employee finger tip manufacturing operation aim consumer healthcare manufacturing site pay achieve average score fine state environmental authority business unit site achieve complete require report storage hazardous achieving year ehs global target progress waste target puerto rico pharmaceutical manufacturing site pay analyse performance set target fine environmental protection agency plan excellence result failure fully comply resource conservation recovery act formalise external stakeholder engagement process consumer healthcare manufacturing site pay fine occupational safety health report performance objective administration osha relate noncompliance page osha eyewash requirement begin extend plan excellence receive follow notice violation aim focus fundamental result fine penalty ehs programme address broad environmental sustainability issue require new approach consumer healthcare manufacturing site australia manufacturing process measure progress exceed allowable limit suspend solid wastewater begin review plan excellence extensive consultation key internal external consumer healthcare manufacturing site stakeholder ensure relevant ehs concern exceed permit substance level wastewater need business reflect plan excellence extend plan ehs plan excellence set strategy improve engage external stakeholder key ehs ehs performance tenyear period concern expectation gsk end year period pharmaceutical industry take stock begin extend plan year undertake companywide intranet survey seek comment discussion document review develop plan follow merger glaxo emerge issue business ehs wellcome smithkline beecham align eh system parent company lay hold individual discussion select senior approach establish new ehs framework gsk manager part business hold workshop world gsk site use annual action plan focus effort base ehs professional include session vision select priority issue halfway point strategy corporate ehs team year plan important year aim fundamental ehs manager ehs professional tell want programme place reach set ehs gsk pharmaceutical company target theme year complete core area activity add value programme business gsk corporate responsibility report environment continue want work external organisation site require develop plan address flexible embed ehs business practice weaknesse improvement identify audit adopt approach appropriate auditor monitor site progress implement business unit plan ehs audit process scoring system refine base experience feedback external stakeholder highlight climate change include assess auditor report ensure great pharmaceutical environment policy consistency ehs auditing software available use chemical key area concern tell intranet help site auditor track progress gsk forefront ehs sustainability issue exert positive influence eh certification industry supply chain request audit committee board director gsk embark programme achieve publish feedback discussion iso ohsa certification consultative document comment additional site achieve certification international internal stakeholder gsk new ehs external environmental management standard iso stakeholder panel stakeholder engagement achieve certification international health information safety standard ohsa bring total expect publish renew year ehs plan dual certify site certify site leave gsk excellence mid network mean pharmaceutical consumer vaccine manufacture site audits certification certify site certify iso audit programme require manufacture site utility area certify certify site site audit internal auditor certify china egypt france germany india italy mexico lead auditor international environment health poland saudi arabia spain turkey kenya safety management standard iso ohsa assess eh management system continue work increase number standard implement certify site encourage site volunteer site comply key legislation revise certification launch pilot project audit process focus significant health safety investigate feasibility certify research risk environmental impact frequency site development site position audits determine factor ehs risk global certification profile performance stakeholder engagement end assess performance frequently engage hoc meeting facility small commercial site self range external stakeholder help assessment internal audit audit site understand perspective identify emerge average score site achieve score issue step internal external regard unacceptable engagement ehs issue average score exceed target aim external engagement correct unacceptable performance continue pursue establish stand panel external stakeholder improvement achieve good practice provide ongoing advice comment eh site spain achieve performance panel facilitate environment leadership score seven council independent charity bring people achieve score develop longterm solution environmental issue member include representative good performance environmental issue customer supplier regulator environmental air emission ozone deplete substance waste organisation socially responsible investor management site generally weak biodiversity risk assessment selfaudite selfaudit panel meet time september achieve big improvement year review draft position paper pharmaceutical process risk management environment climate change policy use chemical issue identify important previous gsk corporate responsibility report environment continue stakeholder discussion member want biodiversity effectively audit programme leadership issue provide well sponsor policy group green alliance explanation papers fit ehs conduct study achieve well environmental strategy comment consider internal regulation discussion finalise position paper conscious stakeholder engagement approve corporate executive team activity heavily focus begin position paper available relevant explore way extend europe section site year panel review proposal revise ehs site engage stakeholder locally plan excellence member express desire example open day newsletter forefront ehs sustainability issue exert community project positive influence industry supply chain comment panel consider regulation develop plan gsk keen proper measure place protect environment safeguard development launch internal engagement new medicine engage regulatory regularly gather staff feedback employee agency europe usa issue survey intranet conduct pharmaceutical environment pie extensive survey view employee environmental risk assessment pharmaceutical ehs plan feedback revise develop plan excellence engage newly establish intergovernmental task force pie trade employee tell association phrma ehs strategy add value gsk business active member association british right thing pharmaceutical industry work group pie employee want gsk liaise environment agency pharmaceutical company ehs collaborate sweden participate initiative organise major player industry trade association lif develop voluntary scheme need embed eh business classify pharmaceutical environmental system instill culture employee effect scheme publish contribute eh httpwwwfassse initial set pharmaceutical evaluate gsk champion transparency ehs european trade association efpia track influence new contribute development guideline regulation involvement trade environmental risk assessment pharmaceutical association european medicine evaluation agency emea need address ehs issue contract guideline expect finalised manufacturing welcome introduction formal requirement plan excellence flexible conduct environmental risk assessment establish allow different rate progress different part eus new medicine legislation gsk lobby business environmental impact pharmaceutical partnership regulate solely european agency partner number environmental evaluation medical product organisation specific area example propose framework registration evaluation work forum future evaluate role authorisation chemical reach believe pharmaceutical company sustainable society lead duplication effort place work environmental organisation unnecessary burden pharmaceutical industry earthwatch institute europe look way address gsk corporate responsibility report environment continue training awareness awareness raise employee awareness environment health use mean raise awareness ehs issue safety issue improve skill complement training programme train key part eh programme employee chief executive officer eh excellence awards level need understand ehs issue scheme recognise outstanding effort ehs help work environment example employee raise profile issue business handle waste gsk site need know property regulation govern disposal publish regular bulletin distribute material recycle site post bulletin board bulletin circulate help employee deal issue include article ehs internal magazine meeting bulletins information intranet site gsk spirit manufacturing magazine site specific training event newsletter intranet site myehs community contain link run environment week june coincide range programme include ehs manager world environment day information kit information system contain policy standard send site help develop idea plan guideline tool training material example good activity gsk employee practice news provide customise site worldwide take environment management report ehs performance site week activity focus issue varied ehs training accessible mylearning biodiversity sustainable purchase waste gsk online training service management training encourage employee consider environmental training take place site level accordance issue outside workplace minimizing ehs standard training ehs requirement household waste energy water conservation programme routinely include site induction encourage use fuelefficient vehicle train new employee regularly assess additional need sure match employee responsibility eh excellence awards local regulatory requirement chief executive officer eh excellence awards recognise reward gsk site innovation eh carry additional ehs management community partnership green chemistrytechnology training consumer healthcare regional ehs initiative environment health pharma supply organisation site visit safety winner receive trophy select oneonone training send ehs essential cdbased charity receive donation gsk compliance tool sale office world improve ehs awareness vanguard award introduce give discretion ceo honour recur last hold regional meeting far reach accomplishment ehs mexico china spain ehs employee health professional share information good practice fourth year award employee site take entry country meeting include training ehs management system application gsk business sector audit audit hazardous waste disposal site injury manufacturing commercial illness report ergonomic risk assessment resilience time entry facility management team mental wellbeing winner choose panel include expert ehs manager encourage attend conference academia government ngo training program sponsor local environmental project represent site europe north america organisations academic institution asia receive honours win project cover area diverse safe driving programme new product process use energy reduce waste gsk corporate responsibility report environment continue award winner new manufacturing process diabete drug reduce number stage require synthesis vanguard award increase yield reduce waste rajahmundry india receive vanguard avoid use hazardous material award recur last far reach accomplishment ehs placetonbridge united kingdom development environmentally friendly process rajahmundry horlick relate product manufacture gwf outstanding record ehs excellence award receive place award tonbridge develop new process synthesise second place award special potential asthma drug cheap readily available commendation year receive material reduce health safety concern place eh initiative category rate solvent require manufacturing ehs community partnership entry demonstrate ehs initiative environment continue passion build good relationship place rajahmundry india use methane gsk local community imaginative environment health safety partnership waste management review reveal gsk site achieve methane generate rajahmundry effluent accreditation international standard social treatment plant burn flare stack ehs accountability follow iso ohsa team divert methane use fuel site accreditation environment health safety canteen instead liquefy petroleum gas community partnership second placerixensart wavre belgium placearanda spain support implementation management green space agenda schools rixensart wavre site belgium teams agenda emerge earth summit rio develop manage green space develop janeiro plan sustainable development number short medium term project protect aranda contribute introduction natural environment improve biodiversity school local community promote environmental site education placethane india water conservation second placenabha india ignite mind build site carry water conservation project awareness road safety include raise employee awareness focus project aim raise children awareness safe initiative harvesting rainwater reuse drive road safety government school introduce water save recovery measure nabha reach total child site heating cool system recycle treat effluent water gardening green chemistrytechnology placetonbridge united kingdom development green process gwa new manufacturing process antiretroviral drug gwa significant environmental benefit cost saving produce solid waste send landfill reduce liquid waste use energy second placeresearch triangle park united states america development manufacture route gwx gsk corporate responsibility report environment continue progress target wastewater quality measure chemical oxygen demand ehs plan excellence identify target area interim target halfway plan nonhazardous waste dispose period review progress target nearly achieve year begin work extend plan year volatile organic compound emit air achieve target miss target achieve ozone depletion potential ancillary equipment target achieve hazardous waste dispose energy use waste recycle global warming potential energy use chart summarise progress ozone depletion potential production inhaler comparison target unit sale water consumption target achieve target unit sale compare baseline performance target energy warming odp duction water cod azardous waste bal pro target achieve performance target energy consumption global warming energy ozone depletion potential production water consumption chemical oxygen demand wastewater nonhazardous waste disposed tnemevorpmi gsk corporate responsibility report environment continue target achieve target unit sale compare baseline performance target voc ancillar wast recycle zard wast target achieve performance target volatile organic compound emission air ozone depletion potential ancillary equipment hazardous waste disposed waste recycled tnemevorpmi gsk corporate responsibility report environment continue performance affect significant business material efficiency change outsource reduce improve efficiency convert raw water consumption improve wastewater quality material finish product important objective case solvent recovery product transfer environmental sustainability help reduce new product introduction difficult consumption natural resource waste generation achieve target cost production believe able meet target energy consume double material efficiency new process associate global warming potential largely come chemical development achieve significant improvement energy saving primary material efficiency active pharmaceutical ingredient manufacturing plant research development tonne active pharmaceutical ingredient energy increase activity tonne input chemical new process propose target new miss target recycle disposal year plan hazardous waste fourfifth solvent performance affect complex mixture effort support drug regulator factor hand food drug administration fda fda focusse process technology recommend phaseout old product year pharmaceutical manufacturer increase focus step contribute reduction solvent manufacturing process waste pharmaceutical industry tend use new product tend few raw material kilo finished product manufacturing step old product mean process sector agrochemical fine solvent energy chemical industry pharmaceutical process typically site modify equipment recycle solvent complex usually involve separate operation receive process move require relatively large amount solvent facility previous year typically industry use material kilogram active pharmaceutical ingredient produce material efficiency compare new product mean pilot plant run fine chemical bulk chemical manufacturing plant time adjust represent waste valuable resource financial solvent recycling operation new solvent environmental consequence gsk aim time adjust solvent recovery improvement future operation new product approach address ehs issue include case site need refurbish solvent minimising material flasc green recovery equipment dispose solvent chemistry tool product design include mass ordinarily recover reuse material lifecycle assessment plan year interim target material impact chemical development scientist construction link plan target especially quality issue minimise align gsk business driver state timescale develop manufacturing process aspiration environmental sustainability conflict improve material efficiency consult internally externally plan begin place high priority improve ensure reasonable reflect measure use material bring drive positive practice business align manufacturing team increase focus material stakeholder expectation extensive consultation efficiency product development stage mean plan ready publication select exist product use key measure mid production efficiency detail performance show section mass productivity mass material report process compare mass product produce gsk corporate responsibility report environment continue reaction mass efficiency rme give measure case study efficiency put key building block drug molecule exclude large material efficiency tonbridge volume solvent normally gsk research development site tonbridge medium chemical reaction material dramatically improve material efficiency essential reaction process develop robust manufacturing process make dramatic improvement antiretroviral compound treat hiv material efficiency example team tonbridge increase production mass efficiency original process require substantial energy production antiretroviral drug manufacturing dealing waste chart show substantial efficiency improvement hazardous solvent dimethylformamide acid development phase new compound methanesulfonic final process base example demonstrate potential chemistry use hazardous improvement scale improvement material achieve process aim build new process increase mass efficiency success manufacturing ehs plan increase tonbridge excellence include improvement target material team identify effective reagent efficiency product emerge potential substitute gsk process process require energy original route cycle time shorter use low processing temperature reduction contaminate aqueous waste result significant energy saving waste require energy intensive incineration tonbridge estimate new process require twothird incineration energy waste disposal peak production rate avoid carbon dioxide emission year equivalent drive average family car million mile tonbridge place green chemistrytechnology section ehs excellence awards work process gsk corporate responsibility report environment continue graph show process development reduce material need manufacture drug initial process mass intensity represent number kilogram material produce product ytisnetni ssam develop process drug drug drug drug gsk corporate responsibility report environment continue product stewardship toolkit address environmental issue associate ecodesign toolkit manufacturing product life cycle begin scientist engineer highlight potential ehs issue product design continue manage early development process practicable impact manufacture operation include toolkit currently module contract manufacture eventual disposal refer significantly revise easy product stewardship use continue update appropriate add guide hazardous chemical section focus legislation product design incorporate toolkit available gsk intranet consist environment health safety consideration design new product green chemistrytechnology guide help pharmaceutical environment gsk scientist engineer apply green chemistry understand minimise impact concept achieve efficient use resource pharmaceutical release environment use reduce environment health safety impact specific issue meter dose inhaler minimise cost reduce ehs impact progress target eliminate use material guide contain information range cfc ozone deplete gas product material gsk operation include portfolio solvent avoid guide cover environmental issue solvent selection second deal chemical associate product corporate base selection responsibility website include use genetically green packaging guide assessment tool modify organism use natural resource include guidance business process evaluate potential impact biodiversity research select packaging option pharmaceutical development section report cover approach consumer healthcare business animal testing flascfast lifecycle assessment synthetic product design chemistry webbase tool process launch work incorporate environment health allow bench chemist perform safety consideration design new product streamline lifecycle evaluation environmental ehs staff participation support new impact new exist process base product team use ecodesign material flasc help scientist manager toolkit rapidly identify green material option compare benchmarking process route continue integrate ehs milestone gsk product identify material align process map product development significant lifecycle environmental impact supply process include design provide guidance reduce impact manufacture initiative manufacturing staff train past chemical legislation guide clgis year ehs map process new product stewardship tool identifie chemical legislation part world aim ehs involvement new product team provide phase hazardous substance routine use unique opportunity influence supply chain decision clg incorporate hazard information volume highlight systemic ehs issue early product phase use provide riskbase guidance development process involvement team variety chemical concern form easy responsible product scientist use manufacturing mean residual ehs risk identify manage appropriately module design ensure ehs impact manufacture material process service consider manufacture raw material ultimate fate product waste environment gsk corporate responsibility report environment continue work key extensive internal consultation paper approve group ecodesign toolkit compelling december useful manufacturing scientist engage interagency task force engineer pharmaceuticals environment pharmaceuticals environment environment agency phrma association drug work active pharmaceutical ingredient british pharmaceutical industry respectively absorb patient body material interact governmental group work include absorb eventually area environmental protection agency excrete bodys normal mechanism geological survey establish enter sewage system wastewater treatment plant relationship group work issue europe remove pharmaceutical residue small gsk scientist team expert concentration end river sea area international scientific workshop human wastewater treatment high concentration pharmaceutical environment coauthored enter environment number chapter book human pharmaceutical pharmaceutical detect surface ground assess impact aquatic ecosystem publish drinking water europe raise work provide roadmap industry concern potential impact people animal government academia research area environment contribute antibiotic resistance work phrma develop database feminisation oestrogen effect highly potent scientific literature impact pharmaceutical drug environmental organism presence anti aquatic life collaborate prepare detailed depressant drink water effect wildlife human health environmental risk assessment veterinary drug pain killer regulator frequentlydetecte pharmaceutical acting concern example swedish carbamazepine aspirin paracetamol ibuprofen authority require additional information classify naproxen work ongoing phrma research pharmaceutical environmental impact european improve understand provide datum need union propose extensive environmental testing prioritize investigation product registration investigate mitigation measure takeback scheme water continue comprehensive environmental risk treatment upgrade label revision assessment phate model great model europe active gsk develop business process ensure pharmaceutical ingredient develop allowable daily carry appropriate environmental test environmental intake level human consumption drink risk assessment approval process new water fish consumption noeffect level drug provide regulatory agency aquatic organism quantitative risk assessment evaluate allow mitigation assessment compare predict potential environmental impact environmental concentration work pharmaceutical company assessment publish website university research group develop science peerreviewe scientific literature methodology assess environmental risk underlie environmental fate effect test data pharmaceutical environment increase pharmaceutically active component gskmarkete understand risk example product embed safety datum sheet gsk involve pharmaceutical research sds available website wwwmsds manufacturers america phrma develop gskcom phate pharmaceutical assessment transport evaluation model base specific local hydrology risk assessment carry date indicate population pattern product appear pose appreciable risk human environment base current method action ascertain effect level continue monitor finalise position paper pharmaceutical late scientific study finding improve risk environment develop assessment area gsk corporate responsibility report environment continue meter dose inhaler montreal protocol ban production cfc meter dose inhaler mdi deliver main exempt number essential use include form treatment asthma sufferer mdi plan eliminate use cfc pressurise handheld device use propellant worldwide product portfolio deliver dose medication patient lung commit stop make cfc device develop introduce cfc traditionally country market end propellant nontoxic non request essential use cfc allocation reactive nonflammable odour taste offer selection alternative country patient use mdi propellant release main alternative propellant use hfc atmosphere thousand kilogram affect ozone high global cfc propellant release patient warm potential product data invest heavily dry powder delivery rest world small proportion cfc system use cfc hfcs estimate thousand kilogram escape air production invest million billion inhaler worldwide ozone deplete substance new plant cfcalternative identify issue ozone depletion potential patient use meter dose inhaler tnelaviuqe cfc noillim ozone depletion potential patient use meter dose inhaler year odp note ozone depletion potential chart report ozone depletion potential cfc equivalent define united nations environment programme unep ozone secretariat datum include gsk corporate responsibility report environment continue energy global warming potential note global warming chart increase greenhouse gas atmosphere global warming impact energy calculate think scientist cause rise conversion factor world business earth temperature know global warming burn council sustainable development wbcsdworld fossil fuel heat power release carbon dioxide resource initiative wri greenhouse gas protocol significant greenhouse gas initiative september stationary mobile set target reduce global combustion workbook intergovernmental warming potential energy unit sale panel climate change meet target achieve reduction use conversion factor department unit sale report energy section environment food rural affair calculate gsk global warming impact come mainly business air travel air freight energy facility manufacture investigate assess use update office site account twothird carbon conversion factor energy begin dioxide emission concentrating effort reduce emission work energy use facilitiesinclude energy emission transport compound use consume gsk facility form electricity product steam purchase fuel burn fix combustion equipment site include emergency generator use compound contribute global warming figure include fuel generate steam produce meter dose inhaler ancillary electricity onsite fuel onsite transport equipment compound contribute global energy consumption section report include warming release patient use meter breakdown energy datum dose inhaler include cfc hcfc deplete ozone layer hfcs report emission transportinclude business travel air include ozone deplete compound ozone depletion transatlantic flight flight section product stewardship routine business activity use ozone depleting compound product flight originate large group event sale convention business travel road include carbon dioxide methane waste treatment companyowne vehicle fleet primarily global sale fermentation account global warming fleet product freight air increase global impact warm potential transport mainly continue work minimise energy use improve reporting system emission face significant challenge expected comprehensively collect transport datum growth new product require additional equipment example datum include business air require additional energy work travel include balance growth continue find opportunity international sale fleet travel great efficiency new exist facility datum include employee travel work operation result expect energy use relate collect data flight originate emission reduce unit sale year large group event mode business travel include rail bus calculate performance emission road rail sea freight transport global warming potential decrease central data collection system robust compare area impact small compare air freight transport transport section report include breakdown transport datum ozone depletion datum include cfc release patient use metered dose inhaler otheris equivalents waste treatment fermentation gsk corporate responsibility report environment continue global warming potential tnelaviuqe noillim operation energy transport energy compound global warming potential year operation transport compound total compound contribute global warming include waste treatment fermentation gsk corporate responsibility report environment continue energy consumption emission trading energy use facility account twothird number site participate government gsk global energy consumption emission trading scheme ets help gain million gigajoule energy produce emission experience carbon trading ets voluntary million buy energy scheme reward company low energy taxis electricity small municipal improve energy efficiency site emission steam hot water generate rest site agree target bank spare credit help comply limit subsequent year consult inside outside company sell credit participant scheme position statement future use energy achieve require emission target year draft response stakeholder feedback course target year energy use impact global warming key concern draft position set strategy energy european union trading scheme come force efficiency renewable energy emission trading start phase run site great megawatt instal continued work energy efficiency initiative combustion capacity require participate total demonstrate follow site project gsk site regulate scheme stevenage instal solarpowere street light performance verify external auditor site exceed cap port fairy australia assess wind turbine anticipate overall surplus carbon bioenergy potential credit scheme plan bank nashik india instal solar heating canteen hot credit help comply future limit expect water trade remainder credit research triangle park increase sponsorship performance level state green power programme energy consumption exclude transport add kwh renewable energy total energy consumption increase north carolina power supply decrease energy zebulon save energy well control consumption unit sale decrease laboratory lighting introducing motionactivate meet lighting reduce temperature office target reduction unit sale building degree global manufacturing supply gms research pharma site operation create development great impact gsk strategic energy leadership council bring energy consumption profile account manager common interest energy gsk energy consumption respectively management provide leadership energy matter energy expand council implement energy utility product pipeline initiative save excess million partially offset energy efficiency initiative include energy conservation tracking database increase energy use minimum energy manager energy technology workshop working project improve energy efficiency suzhou china modify chill water system expand activity require equivalent avoid chill air temperature increase energy use low ensure cool water save primary supply antibiotic group gms estimate kwh electricity year reduce total energy use great reduction gsk supply group operation time period significant reduction result focus energy efficiency coordinate effort identify implement site specific programme site supply group gsk corporate responsibility report environment continue energy consumption exclude transport seluojagig noillim target unit sale percentage baseline axis nontransport fuel electricity purchase steam purchase energy consumption exclude transport year steam electric nontransport fuel total gsk corporate responsibility report environment continue energy consumption business exclude transport primary supply antibiotic commercial biological regional pharma supply new product global supply research development consumer healthcare supply primary supply antibiotic new product global supply regional pharma supply consumer healthcare supply biologicals research development commercial total million gigajoule gsk corporate responsibility report environment continue global warming potential energy case study total global warming potential energy use facility increase saving energy waste methane decrease global warming potential gsk consumer healthcare site rajahmundry unit sale decrease india capture methane generate anaerobic meaning meet target digestion wastewater sludge previously reduction unit sale waste use instead liquefy petroleum sulphur dioxide nitrogen oxides gas lpg site canteen use methane kilogram nox kilogram correct double cap project complete emit site coalfire power march reduce risk storing lpg cylinder conserve resource save money eliminate waste note energy chart methane generate factorys effluent energy consumption facility define treatment plant previously majority highly energy consume form electricity steam flammable gas burn flare stack purchase fuel burn fix combustion production distil water use equipment site include emergency generator methane project examine gas figure include fuel generate steam productive use identify canteen fuel electricity onsite fuel onsite transport good solution global warming potential energy use factory lay pipeline anaerobic digestion facility calculate conversion factor canteen buy new stove adapt world business council sustainable development burn methane lpg wbcsd world resource initiative wri greenhouse gas protocol initiative september stationary project reduce lpg mobile combustion workbook site canteen saving cylinder gas intergovernmental panel climate change year worth store few lpg cylinder improve safety significantly reduce nox calculate coal risk explosion gsk facilitiesin india use coal conversion factor national atmospheric use methane award place ehs emission inventory national methodology initiative environment category ceo ehs excellence awards gsk corporate responsibility report environment continue global warming potential energy exclude transport tnelaviuqe noillim target unit sale percentage baseline axis nontransport fuel electricity purchase steam purchase global warming potential energy exclude transport year steam electric nontransport fuel total gsk corporate responsibility report environment continue global warming potential energy exclude transport business biological research development commercial new product global supply regional pharma supply consumer healthcare supply primary supply antibiotic primary supply antibiotic new product global supply regional pharma supply consumer healthcare supply biological research development commercial total million equivalent gsk corporate responsibility report environment continue transport encourage employee use video estimate transport account teleconference possible reduce air travel total global warming impact emit virtual meeting software available employee approximately million kilogram make presentation collaborative work transport average gsk employee conduct video meeting teleconference virtual meeting business air travel account half month travelrelate emission employee travel total million kilometre plane performance decrease result million total global warming potential transport increase emission include transatlantic flight increase flight mainly improve report routine business activity travel originating system collect comprehensive transport datum relate large group event sale example datum include business air convention travel include international sale fleet believe global sale fleet drive total underestimate global warm potential million kilometre business travel result transport robust system million collect group air travel originate addition business travel transport product manufacturing plant distributor gsk product transport total million note transport chart kilometre majority air freight datum business air travel include transatlantic flight estimate air freight result million flight increase routine business activity flight originate improve data collection large group event sale convention continue business growth datum business travel road primarily global sale fleet collect datum mode increase source china business travel include rail bus rise clinical trial conduct outside air freight cover global route launch number initiative reduce calculate emission road rail sea impact transport product include freight transport central datum collection consolidate freight shipment pharmaceutical system robust area impact consumer product transport consolidate small compare air freight shipping point make use round tripping transport manage inbound freight truck return convert air transport sea transport use conversion factor department possible environment food rural affair calculate business air travel air freight green travel plan number site encourage employee reduce environmental impact travel work example gsk house brentford privilege parking space give car sharer driver fuel efficient car bus run local train station change room shower provide cyclist discount bicycle equipment repair gsk corporate responsibility report environment continue global warming potential transport business travel road business travel air product freight air tnelaviuqe noillim global warming potential transport year freight business air business road total gsk corporate responsibility report environment continue water case study water valuable natural resource need conserve protect pollution water water conservation thasne india conservation particularly important area gsk site thane near mumbai india water shortage common manufacture medicine local market thane gsk use water manufacturing process introduce measure conserve minimise water product cool clean general site use include rainwater harvesting improve use include drink food service sanitation efficiency instal water save technology water site use varie accord site reduce water activity place primary supply site consumption kilolitre year manufacture active pharmaceutical ingredient kilolitre year typically heavy user water site site locate monsoon region mean manufacture vaccine produce drink involve experience irregular rainfall water shortage research development commercial site dry season problem amplify typically use increase urbanisation agricultural development gsk water standard require site minimise water thane receive water municipal supply use reuse water feasible site require use cool generate steam boiler minimise potential environmental impact garden discharge wastewater thane instal rainwater catchment device roof water use near site boiler cool tower rainwater pump storage tank ready immediate use million cubic metre water pump borewell replenish water average industry base benchmarking table result water consumption peak major pharmaceutical company source monsoon month september drop water mainly municipal water supply wells kilolitres kilolitre borehole small source measure introduce save water include steam recovery device boiler total water consumption increase prohibit hose cleaning plant floor instal water consumption photosensor urinal instal foot unit sale decrease operate tap site canteen mean meet target cut water use unit sale mainly consolidate thane instal drip irrigation system garden primary manufacturing site follow merger sprinkler system change reduce outsourcing fermentation process water lose evaporation change garden include altering planting introduce water conservation measure season coincide wetter month water plant example site thane india early morning allow grass ceo ehs excellence awards water conservation grow long hold soil moisture measure similar project submit site pakistan india indonesia poland canada thane award place environment category ceo ehs excellence awards note water use chart water conservation improvement water use include water source wellsborehole municipal source mainly wastewater external industrial source datum include water manufacturing process general site use water incorporate product gsk corporate responsibility report environment continue water consumption water consumption year wellsborehole municipal total mainly wastewater external industrial source sertem cibuc noillim target unit sale percentage baseline axis wellsborehole municipal source gsk corporate responsibility report environment continue water consumption business commercial primary supply antibiotic biological new product global supply research development regional pharma supply consumer healthcare supply primary supply antibiotic new product global supply regional pharma supply consumer healthcare supply biological research development commercial total million cubic metre gsk corporate responsibility report environment continue wastewater note wastewater cod chart generate million cubic metre wastewater volume include manufacturing site wastewater manufacturing process process wastewater sanitary food service site operation wastewater decrease mainly consolidate primary manufacturing site follow merger wastewater quality measure chemical oxygen outsourcing fermentation process demand cod measure oxygen reuse recover recycle total wastewater require chemically oxidise organic inorganic compound present water gsk ehs standard require site reuse water feasible ensure wastewater cod measure wastewater leave treat discharge way minimise adverse site follow onsite treatment environmental impact site discharge wastewater municipal treatment facility prior treatment large site especially primary manufacturing site onsite wastewater treatment system site permit discharge wastewater direct sea site india implement zero wastewater discharge programme reuse recycling wastewater use process wastewater watering plant tree help provide shade improve appearance site source food employee discharge wastewater water body municipal sewer site xochimilco mexico use process wastewater watering garden site washing vehicle window use require drink water site turkey philippine reuse wastewater assess quality wastewater measure chemical oxygen demand cod oxygen require chemically oxidise organic inorganic compound present water low cod clean water total cod decrease compare reduction site ulverston outsourcing fermentation process cod unit sale decrease mean achieve target reduction unit sale gsk corporate responsibility report environment continue wastewater volume wastewater volume year sea estuary sewer total include direct river reusedrecoveredrecycle sertem cibuc noillim direct sea direct estuary municipal sewer gsk corporate responsibility report environment continue wastewater volume business commercial new product global supply primary supply antibiotic regional pharma supply biological research development consumer healthcare supply primary supply antibiotic new product global supply regional pharma supply consumer healthcare supply biological research development commercial total million cubic metre gsk corporate responsibility report environment continue wastewater chemical oxygen demand noillim target unit sale percentage baseline axis direct sea direct estuary municipal sewer wastewater chemical oxygen demand year sea estuary sewer total include reusedrecoveredrecycle onsite irrigation gsk corporate responsibility report environment continue wastewater chemical oxygen demand business research development new product global supply biological regional pharma supply primary supply antibiotic consumer healthcare supply primary supply antibiotic new product global supply regional pharma supply consumer healthcare supply biological research development commercial total million gsk corporate responsibility report environment continue waste gsk heritage company spend clean site research production commercial activity year continue clean produce waste aim manage safely site waste disposal site gsk responsibly manage waste generate responsible party final disposal want eliminate waste reduce reuse material continue work reduce waste especially possible recycle waste dispose remain hazardous waste material efficiency material sensitively aspiration minimise number solvent use small amount dispose generate different kind waste different part operational excellence initiative start business strong focus elimination type production hazardous waste solvent waste manufacturing process reflect chemical application ceo ehs excellence awards quality laboratory small amount project involve eliminate recycle waste chemical include product intermediate performance waste cover follow break glassware plastic page office paper standard commercial waste hazardous waste renovation place production office lab hazardous waste consist space produce nonroutine waste solvent production process obsolete equipment office furniture structural dispose lubricant fluorescent light material research waste include animal carcase lab generate active ingredient pharmaceutical small quantity radioactive waste highly product manufacture chemical process regulate mean significant proportion waste regulation vary widely world classify hazardous contain solvent choice solvent reuse recycle material chemical process report hazardous possible main disposal option solvent waste separate nonhazardous identify non incineration aim use incineration energy routine waste construction demolition rubble recovery possible volume depend building activity tend inconsistent main focus work improve material efficiency reduce total solvent use production facility segregate waste reuse send recycling dispose million hazardous waste incinerate landfill incineration usually exclude demolition construction waste prefer choice deal solvent solvent rest general site waste reuse recycle site try use waste management chemical biological radioactive waste company use incinerator recover energy hazardous waste dispose burning material incinerate energy recovery incinerate aim use reputable waste handling company energy recovery remain waste waste disposal require disposal contractor comply dispose licensed landfill site ehs requirement local regulation internal eh audit team audits waste disposal contractor sure handle waste appropriately past waste chemical handling practice long follow contaminate land groundwater continue clean site deal health environmental hazard gsk corporate responsibility report environment continue performance note hazardous waste chart total hazardous waste dispose decrease hazardous waste external definition constitute dispose unit sale decrease waste vary gsk report purpose material increase meaning meet consider waste long fit originally target reduction unit sale intend purpose previous trend reduce hazardous waste unit hazardous waste dispose include disposal landfill sale reverse combination factor incineration gsk property gsk hazardous waste solvent plant incineration energy recovery mean burn schedule closure dispose redundant solvent material result energy incineration stock impact datum addition energy recovery mean burn material change production plant include bring energy heat generate hazardous inhouse process previously undertake waste dispose include recycle onsite contract manufacturer move exist process offsite nonroutine waste site engineer continue assess consistent reporting gsk consider waste optimise new move process reduce solvent hazardous exhibit number property use increase recycling resume define basel convention unite downward trend nations environment programme unep include solvent recovery affect factor propertie flammability explosivity water air reactivity corrosivity oxidise potential acute repair solvent recovery equipment chronic toxicity ecotoxicity infection addition site result complete shutdown nature potential impact recovery operation commercial recovery operation research development activity radioactive waste available solvent normally recover define hazardous bioengineered incinerate instead biohazardous waste include hazardous waste new product new solvent continue come line time site gear solvent waste consider nonhazardous recovery recycle new material exhibit hazardous property note pilot plant produce new product clinical trial work wide range different solvent recycle practical primary site difficulty handle solvent receive result move process site year site begin recover move improve solvent recovery decrease solvent dispose new site acquire contribute additional million total solvent recycle year gsk corporate responsibility report environment continue hazardous waste dispose noillim target unit sale percentage baseline axis incinerate energy recovery incinerate energy recovery landfill hazardous waste dispose year recovery recovery landfill total gsk corporate responsibility report environment continue hazardous waste dispose business commercial consumer healthcare supply new product global supply regional pharma supply primary supply antibiotic biological research development primary supply antibiotic new product global supply regional pharma supply consumer healthcare supply biological research development commercial total million gsk corporate responsibility report environment continue hazardous waste dispose source noillim solvent waste site waste hazardous waste dispose source year solvent site total include chemicalbiologicalradioactivepharmaceutical waste gsk corporate responsibility report environment continue nonhazardous waste note nonhazardous waste chart nonhazardous waste general material external definition constitute office waste paper kitchen waste nonhazardous waste vary gsk report purpose material substance manufacture small consider waste long fit originally biological waste treat intend purpose hazardous include construction demolition rubble similar material relate day nonhazardous waste disposal include disposal today operation describe separately non landfill incineration gsk property routine waste dispose million incineration energy recovery include process nonhazardous waste result beneficial energy resource recovery include small compost incineration continue look way reduce waste energy recovery include process undertaken waste management review site result beneficial energy resource recovery non performance hazardous waste dispose include recycle total nonhazardous waste low onsite offsite nonroutine waste low weight dispose unit biological waste render nonhazardous sale decrease year treatment consider nonhazardous waste means considerably beat target reduction unit sale gsk corporate responsibility report environment continue nonhazardous waste dispose noillim target unit sale percentage baseline axis incinerate energy recovery incinerate energy recovery landfill nonhazardous waste dispose year recovery recovery landfill total gsk corporate responsibility report environment continue nonhazardous waste dispose business biological consumer healthcare supply commercial regional pharma supply new product global supply research development primary supply antibiotic primary supply antibiotic new product global supply regional pharma supply consumer healthcare supply biological research development commercial total million gsk corporate responsibility report environment continue nonhazardous waste dispose source noillim site waste nonhazardous waste dispose source year site total gsk corporate responsibility report environment continue recycle recycle hazardous nonhazardous waste aim minimise environmental impact cost material waste large waste component solvent manufacturing process solvent purify site reuse original manufacturing process sell solvent commercial reprocess company include recycle statistic solvent recycle way usually incinerate recycle nonhazardous waste glass plastic usually mean send reprocess reuse new product performance recycle million waste nearly million waste generate twothird total waste recycle hazardous waste primarily solvent proportion waste recycle higher decrease mainly generate waste mean meet target increase proportion waste recycle production change year contribute incineration solvent waste recycle small proportion large primary manufacturing site track recycling solvent reverse decline site continue difficulty recovery site gsk corporate responsibility report environment continue proportion total waste recycle proportion total waste recycle year waste recycle target percentage baseline axis waste recycle gsk corporate responsibility report environment continue proportion total waste recycle business primary tibiotics product supply egional pharma supply umer healthcare supply biological researc ven opment commercial proportion total waste recycle business primary supply antibiotic new product global supply regional pharma supply consumer healthcare supply biological research development commercial gsk corporate responsibility report environment continue total waste recycle noillim hazardous nonhazardous total waste recycle year hazardous nonhazardous total gsk corporate responsibility report environment continue nonroutine waste nonroutine waste primarily build material site demolition construction activity small remediation project dispose landfill incineration million nonroutine waste recycle million performance waste fluctuate year depend plant upgrade site closure new building vaccine plant account nearly half nonroutine waste send waste landfill plant able provide excavate soil building expansion company clean fill note nonroutine waste chart external definition constitute waste varie gsk report purpose material consider waste long fit originally intend purpose nonroutine waste disposal include disposal landfill incineration gsk property incineration energy recovery include process result beneficial energy resource recovery recycle nonroutine waste feasible gsk corporate responsibility report environment continue nonroutine waste noillim recycle incinerate energy recovery incinerate energy recovery landfill nonroutine waste year recycle recovery recovery landfill total gsk corporate responsibility report environment continue ozone depletion performance ozone layer essential human survival ozone deplete substance release ozone filter harmful ultraviolet ray sun production activity depletion ozone deplete substance odss include chlorofluorocarbon cfcs hydrochlorofluorocarbon substance factor potential hcfcs halon cfcr cfc main odss use propellant gas cfcr meter dose inhaler mdi asthma sufferer cfc release patient use inhaler total ozone depletion potential production decrease thousand kilogram cfc propellant ozone depletion release patient product potential production unit sale decrease stop make product mean information cfc release patient use beat target reduction unit sale compile outside require regulation small cfc production cfccontaine mdi decrease thousand kilogram release worldwide cfc lose production decline production offer selection alternative long manufacture cfccontaine mdi odscontaine inhaler country plan europe continue eliminate use odss product portfolio manufacture bangladesh china india meter dose inhaler pakistan end use odss cool system ancillary use gsk facility switch hydrofluorocarbon hfc cool system hfcs note ozone depletion potential chart deplete ozone layer contribute global report ozone depletion potential cfc warm ozone depletion potential ancillary use equivalent define united nations unit sale decrease mean environment programme unep ozone secretariat miss target completely eliminate emission recognise way eliminate cfc cool system new strategy focus instal new equipment achieve set new target eliminate cfc use line regulation base montreal protocol ozone deplete substance manufacture small proportion cfc propellant meter dose inhaler mdi release manufacturing process work eliminate use ozone deplete substance mdi switch hfc dry powder inhaler gsk corporate responsibility report environment continue ozone depletion potential production use tnelaviuqe cfc noillim target unit sale percentage baseline axis production ozone depletion potential production use year production gsk corporate responsibility report environment continue ozone depletion potential production use business regional pharma supply new product global supply primary supply antibiotic new product global supply regional pharma supply consumer healthcare supply biological research development commercial total thousand cfc equivalent gsk corporate responsibility report environment continue ozone deplete substance ancillary total ozone depletion potential ancillary increase equipment equipment replacement use ozone deplete substance odss primarily maintenance large site figure decrease cool system switch ozone depletion potential hydrofluorocarbon hfc ancillary equipment ancillary use unit sale increase hfcs deplete ozone layer contribute decrease global warming miss target eliminate ozone deplete odss mainly cfcs hcfc seal inside cool emission ancillary use prove possible system release event leak eliminate emission servicing maintenance maintenance cool equipment mean need upgrade replace equipment use nonozone closely monitor equipment place deplete gas new cool system use recommendation alternative refrigerant new ozone deplete gas introduce equipment recognise way eliminate accordance regulatory requirement retrospect emission eliminate cfc cool system believe target set unrealistic give new strategy focus replace equipment potential improvement set new target eliminate cfc use line regulation performance note ozone depletion potential chart report ozone depletion potential cfc ozone deplete substance release ozone equivalent define united nations ancillary activity depletion environment programme unep ozone secretariat substance factor potential cfcr cfcr hfcr hfcr rafx rafx methyl bromide gsk corporate responsibility report environment continue ozone depletion potential ancillary use tnelaviuqe cfc noillim target unit sale percentage baseline axis ancillary ozone depletion potential ancillary use year ancilliary gsk corporate responsibility report environment continue ozone depletion potential ancillary use business biological consumer healthcare supply new product global supply research development commercial regional pharma supply primary supply antibiotic primary supply antibiotic new product global supply regional pharma supply consumer healthcare supply biological research development commercial total thousand cfc equivalent gsk corporate responsibility report environment continue volatile organic compound note voc chart use volatile organic compound voc mainly emission volatile organic compound voc solvent primary manufacturing operation include fugitive source evaporation release million kilogram voc leak measure gsk manufacturing operation atmosphere research development facility voc react nitrogen oxides presence vocs react nitrogen oxide presence sunlight create ozone low atmosphere sunlight create ozone low atmosphere result smog factor human respiratory result smog factor human respiratory illness workplace exposure certain voc pose illness report photochemical ozone creation health risk potential pocp ethylene equivalent conversion performance ethylene equivalent base european total voc emit air decrease chemical industry council cefic responsible care voc emit air unit sale decrease hse reporting guideline vocs mean miss target reduction unit sale achieve substantial reduction case study narrowly miss target reduce solvent use waste achieve reduction rationalise manufacturing operation follow merger manufacturing expect set target decrease gsk site research triangle park site ulverston research new drug treatment type outsourcing manufacturing improve data diabete metabolic syndrome site collection contribute develop new manufacturing process drug reduce waste solvent use eliminate photochemical ozone creation potential decrease use harmful substance previous manufacturing process drug timeconsume inefficient involve step low production efficiency new process develop rtp number environmental health safety benefit process quick involve step solvent need aid synthesis step few step mean solvent require result solvent voc emission reduce waste produce reduce importantly new process avoid use harmful alkylate agent hazardous rtp award second place green chemistrytechnology category ceo ehs excellence awards achievement gsk corporate responsibility report environment continue volatile organic compound emit air noillim target unit sale percentage baseline axis voc volatile organic compound emit air year voc gsk corporate responsibility report environment continue volatile organic compound emit air business research development new product global supply primary supply antibiotic regional pharma supply primary supply antibiotic new product global supply regional pharma supply consumer healthcare supply biological research development commercial total million gsk corporate responsibility report environment continue photochemical ozone creation potential tnelaviuqe enelyhte noillim photochemical ozone creation potential year pocp gsk corporate responsibility report environment continue biodiversity biodiversity manage site level issue impact local gsk site require maintain diversity plant animal specie important sustainability aim identify assess potential impact activity sure activity adversely affect biodiversity local habitat protect local habitat wildlife improve site act minimize adverse effect activity surrounding commitment local important habitat community enhance biodiversity feasible wildlife threaten new site development exist operation affect natural habitat monitor impact ensure action remain effective habitat severely damage depletion water protect enhance local biodiversity resource use water particularly sensitive example water information water management nabha india develop biodiversity management investigation collection natural product plan develop ecoforestry acre land disruptive need carefully manage water discharge site minimise adverse effect limited use memphis tennessee team natural product research happen north american butterfly association naba improve aim ensure investigation collection use habitat introduce specie indigenous biological material purpose research adjacent president island manufacturing adversely affect biodiversity crawley work specialist woodland contractor local wildlife trust enhance area case study work ribena supplier improve crop field edge farm biodiversity draw environmental action plan measure include trim hedge frequently gsk heritage company make certain time year hedgerow green ribena year buy uks veins countryside provide food shelter blackcurrant crop grower breed site native specie frequent farmer family business supply trim year allow hedge grow berry ribena generation produce fruit provide food bird bat small take year blackcurrant bush mammal insect farmer leave uncultivated produce fruit big investment buy margin field protect hedge directly grower agree seven year spray add bat bird box planting contract help plan ahead new tree blackcurrant farming mechanised berry joint project grower include research shake bush harvesting machine department environment food pick hand enable reduce rural affair increase vitamin content number blackcurrant supplier work ribena closely small group grower gsk help establish blackcurrant grower group close relationship lead farming meet quarterly share good practice environmental improvement initiative blackcurrant foundation organisation promote partnership wildlife trust increase health environmental benefit blackcurrant biodiversity similar initiative underway grower help wildlife trust grower introduce new zealand supply blackcurrant ribena simple change improve habitat animal sell asia gsk corporate responsibility report environment continue oak woodland site create pond site score base performance gsk thin tree instal bird nesting box ehs standard key supplier supplementary quantitative risk assessment scheme dartford support partnership include recommendation follow audit monitor uks environment agency work progress particular focus poorlyperforme safeguard historic dartford marshe vital supplier safeguard dartford flooding support host rare protect specie include water vole significant improvement curtail end procurement site meet minimal rixensart wavrenordin belgium close performance score ehs standard woodland work improve score unacceptable rating quantitative risk biodiversity year plant assessment contract manufacturer minimum indigenous specie shrub maximising use score increase flower plant encourage bee insect requirement establish orchard old variety apple pear plums rixensart celebrate fifth supplier audits cover basic question human anniversary nature path employee create right human right supplier join usepa green supplier network supplier gsn wwwepagovopptintrphomegsnprogramhtm green supplier network programme help supply chain complex mean assure small mediumsize supplier reduce ehs performance supplier challenge environmental impact gsk support programme currently provide oversight audit ehs issue initiative undertake operational centrally approximately critical supplier excellence theme specific supplier contract manufacturer material exclusively gsk base primarily europe supplier performance north america asia pacific carry sitebased ehs audits approximately half potentially new select negotiating manage key supplier site audit producer supplier material product manufacturing ingredient raw material manufacturing supply chain ehs lossprevention issue supply chain find wide variation performance account include provide information score range supplier ehs risk associate gsk material determine unacceptable gsk audit produce handling assessment standard decide proceed carry ehs audits signing contract supplier significant improvement significant new key supplier contract contain remain audits site supply requirement base global ehs standards pharmaceutical consumer healthcare product subsequent ehs involvement base assessment material research development performance ehs risk focusse ehs standard range threat continuity supply general supplier base north america europe hazard associate manufacturing process perform performance asia pacific materials variable case significant gap ehs standard environmental impact find apparent instance noncompliance regulatory requirement universal declaration human right core relevance supply essential medicine labour standard set international labour key supplier present great risk gsk orgainsation ilo issue receive great scrutiny gsk corporate responsibility report environment continue report ehs performance ehs information collect possible select supplier datum currently include ehs performance chart contain report subject verification erm request information supplier provide datum provide datum comparative figure supplier produce total material result follow energy use gigajoule water consumption cubic metre hazardous waste dispose nonhazardous waste dispose community investment introduction access medicine research ethical conduct employment practice human right environment community investment value community investment humanitarian relief community partnership support education employee involvement datum summary gsk corporate responsibility report community investment gsk make donation money medicine time equipment support good cause strategy community investment improve health education underserve community support public health initiative local community project world donate medicine support disaster relief effort impoverished community community investment link shortterm awards business benefit intend create commercial market gsk support reputation receive annual scrip award demonstrate commitment tackle healthcare corporate social responsibility gsk role challenge believe profit lymphatic filariasis elimination programme benefit underserved community receive business community big tick responsible company science education programme support barretstown finalist number total community investment value award include million million equivalent pretax profit donation group level business community international award individual gsk site support local community elimination programme objective ensure project sustainable african investor award gsk support longterm continue gsk funding come integrate management childhood end community investment illness imci initiative africa nonprofit organisation expert chamber commerce center corporate field healthcare delivery education help citizenship award education programme ensure give target community need information community investment programme increase healthcare capacity develop country value community investment include access medicine section report gsk donation value million million cover major public health initiative tackle compare million lymphatic filariasis hivaids malaria diarrhoea equivalent pretax profit relate disease figure include medicine worth million section provide information community million donate lowincome patient investment programme cover patient assistance program million million breakdown charitable donation humanitarian product donation underserve community world million donation medicine humanitarian relief include million albendazole tablet lymphatic filariasis natural disaster elimination programme community partnership local support provide total community investment include million corporate level gsk site million cash grant million support science education million management cost employee involvement community gsk member uks percent club company donate pretax profit charitable cause gsk regularly company uks guardian giving list list ftse company percentage pretax profit gsk corporate responsibility report community investment continue contribute charitable cause member uks london benchmarking list base percentage pretax group lbg committee encourage corporate profit donate fourth year philanthropy cecp report donation row big overall giver value line guideline set cecp value donation medicine wholesale acquisition cost line pharmaceutical company wholesale acquisition cost wholesale list price include discount method give total cash product inkind management cost method give million cash product inkind mangement cost breakdown cash give total health education art culture breakdown environment cash give health education art culture environment gsk corporate responsibility report community investment continue humanitarian relief follow hurricane katrina donate medicine value million relief facility states gsk donate essential product antibiotic help include antibiotic vaccine consumer healthcare relief effort disaster area support basic healthcare product toothpaste antacid pain reliever provision impoverished community gsk supply interim shipment medicine donation request government diabete heart disease asthma patient major charitable organisation manufacture lose supply disaster medicine specifically partner enable charity distribute hospital shelter partner hold range medicine stock respond organisation project hope americare promptly emergency work partnership gsk large pharmaceutical company pakistan relief charity include americare direct relief able deliver urgent supply free interchurch medical assistance map international medicine hour earthquake local project hope business product donation include hepatitis limit product vaccine request ministry health away donation carefully manage rely value million give cash donation expertise partner ensure available million south asia earthquake relief fund medicine target community need gsk general manager approve donation destine country avoid conflict community partnership commercial business charity partner support wide range health education require track donation sure reach initiative community operate intend destination dispense appropriately donation centrally gsk site donate medicine disease require support local charity good cause continuous assure supply example community gsk follow world health organization interagency partnership support guideline drug donation state donation response express need send europe prior consent label correctly barretstown ireland lenvol france residential minimum year shelf life member camp seriously ill child fun partnership quality medical donation pqmd develop self confidence gsk give alliance pharmaceutical company charity respectively encourage good practice donation delivery support camp employee time medicine barretstown lenvol gsk employee participate activity donate lifesave medicine worth gsk fund european programme million million support relief effort grant year country supply antibiotic basic medicine change advance disease prevention programme send response south east asian tsunami promote healthy eat exercise aim hurricane caribbean slovakian child live urban housing estate earthquake pakistan children shelter programme spain provide immediate aftermath tsunami donate healthcare homeless abandon child million dose antibiotic prevent beacon hope palliative care programme spread infectious disease affect country child romania commit million million support organisation work relief reconstruction read grow programme italy operation disaster area read aloud help child neuro functional disability endure long hospitalisation gsk corporate responsibility report community investment continue multi coloured live interactive education support parent carer young programme help child disability integrate baby child deal diagnose russian society undiagnosed recur chest problem international gsk phase personal hygiene sanitation education gsk donate year initiative provide education school arthur ashe institute urban health black child kenya uganda zambia nicaragua peru pearl programme provide health education low improve health hygiene fight infectious income neighbourhood reach nontraditional disease commit threeyear funding venue include african american afrocaribbean extend programme bangladesh church barber shop beauty salon laundromat partnership save children usa major public tattoo parlour provide culturally appropriate health initiative information help promote early disease detection encourage people multiethnic community adopt gsk funding number country programme healthy lifestyle grant year continue support children health fund pinoy health pass family health referral management initiative rmi new threeyear provide health education family low income grant million million help rmi continue philippine extend service philadelphia help highrisk attituda positiva use drama school increase homeless child receive specialist medical care awareness education hiv reproductive need health teenager brazil foundation midwife help improve mother child health gsk operate single charitable foundation rural area vietnam bring birth attendant community investment programme ethnic minority group training capital countrybase foundations canada czech republic major hospital france italy romania spain north carolina local foundation support wide range gsk support charitable organisation charity healthcare initiative include gsk france foundation support support medical research undertake charity programme country focus people meningitis british liver trust alzheimer research live hivaid develop country particularly trust samantha dickson research trust africa aim improve healthcare extend partnership british red cross prevention education training give year gateway project new programme implement country scotland gateway help young people disability grant euros gain skill selfconfidence need live gsk foundation canada focus independently gateway work support hospice care help terminally ill patient small group young disabled people help set family foundation support personal goal receive individually tailor training community programme africa include aid orphan support people disability uganda threeyear programme building community visit centre year workshop support vulnerable child luweero district use facility new funding enable gateway extend service scotland share north carolina gsk foundation usa experience health social care provider endow selffunde organisation support initiative area mathematics science health education north carolina foundation award gsk give year grant total million million support british lung foundations baby breathe easy programme funding pilot scheme region gsk corporate responsibility report community investment continue support education support sally ride science festival aim increase girl interest science math technology gsk support education festival feature workshop lead local particular emphasis develop scientific literacy veterinarian astronomer microbiologist encourage generation scientist engineer workshop run parent science education teacher support girl interest gsk support inspire innovative scheme science technology career postdoctoral researcher research education threeyear grant gsk scheme develop partnership imperial college help national board professional teaching london specialist schools academie trust standard increase number science teacher million million donation year north carolina philadelphia area inspire aim raise achievement place postdoctoral researcher specialist science school train teacher support science teaching employee involvement fifth year gsk sponsorship grant gsk employee encourage contribute association science education local community volunteer support science world international hundred employee time good cause education programme enable school child day care support country discuss science issue school science education science internet engineering ambassador scheme partnership grant gsk science educational discovery teacher able participate active assessment cash donation training help teacher improve pupil charity employee voluntary work thinking skill empower responsibility learn gsk investment volunteer excellence programme give gsk commit million million charitable organisation employee year help build new darwin centre natural partner volunteer hour history museum london enable well display year make difference programme museum important collection provide grant education charity employee volunteer increase support initiative country encourage employee improve overall education standard gsk donate money charity match money found partner chamber commerce provide taxefficient way business education network network develop donation accordance local taxation guideline partnership business community usa gsk match donation education provider improve educational standard employee retiree value million bridge skill gap million addition gsk give million continue support range science match donation gsk employee education initiative annual gsk united way campaign science summer free librarybase education programme philadelphia give child chance participate handson experiment science base course gsk donate science summer enable child participate child participate programme launch nearly year ago gsk corporate responsibility report community investment continue case study gift life gsk product donation gsk antibiotic fight common lifethreatening infection donate antibiotic medicine worth million response disaster relief effort travel pack medic humanitarian mission support healthcare provision impoverished community threeyear old rosa angelica pravia thousand people benefit admit hospital remote south america doctor fear infection result meningitis father earn day cleaning pineapple child family afford medicine treat fortunately hospital receive donation medicine map international include gsk antibiotic ceftin day rosa danger doctor say ceftinhad save life product donate response specific request relief charity americare direct relief interchurch medical assistance map international project hope map international use donation gsk antibiotic augmentinand amoxilin travel pack medical mission pack compact fully stock portable pharmacy enable team treat wide range illnesse develop country antibiotic treat infection life threaten map team report recently mission zambia local doctor tell remote village patient resource fill prescription gsk help able patient help medication datum summary introduction access medicine research ethical conduct employment practice human right environment community investment datum summary gsk corporate responsibility report datum summary access medicine number country supply preferentially price arvs number preferentially price combivirtablet ship millions number preferentially price epivirtablet ship million gsk combivirnotforprofit price day voluntary licence grant generic manufacturer gsk arvs number albendazole tablet donate prevention lymphatic filariasis million number country supply albendazole research development gsk animal research facility accredit association assessment accreditation laboratory animal care number trial publish gsk clinical trial register cumulative total ethical conduct number employee complete certification gsk code conduct number contact ethic compliance channel employment woman management grade ethnic diversity people colour ethnic diversity ethnic minority lose time injury illness rate case hour work lose time injury illness rate contractor work site case hour work environment number contract manufacturer audit energy consumption million gigajoule water consumption million cubic metre ozone depletion potential meter dose inhaler tonne cfc equivalent ozone depletion potential production tonne cfc equivalent ozone depletion potential refrigeration ancillary use tonne cfc equivalent volatile organic compound emission thousand tonne global warming potential energy source thousand tonne equivalent hazardous waste dispose thousand tonne community investment total community investment expenditure million value humanitarian product donation include albendazole million value product donate gsk patient assistance program million include arvs sell notforprofit discount price unable collect datum number patient treat include delivery cost mdecin san frontire june report show average cost generic equivalent day lowest price generic equivalent cost day include delivery currently animal research laboratory animal research laboratory trial complete merger create gsk include contact line manager compliance officer confidential integrity helpline offsite post office box